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Despite extensive studies on the pathogenesis of acute Clostridioides difficile (C. difficile) 
infection (CDI), CDI has never been associated with colorectal cancer (CRC). Analyzing 
microbial species sequences from our previous study, we identified C. difficile DNA in the 
subsets of biofilm-positive (BF+) human colonic mucosal homogenates that promoted 
colon tumorigenesis after inoculation into germ-free (GF) ApcMin∆850/+;Il10-/- and 
ApcMin∆850/+ mice or specific-pathogen-free (SPF) ApcMin∆716/+ mice. These results raised 
an unexpected question of whether persistent mucosal colonization of C. difficile 
contributes to human colon tumor development. To address this question, we developed 
a chronic C. difficile infection mouse model in this study that allows sustained and non-
lethal C. difficile colonization for 12 weeks in SPF ApcMin∆716/+ mice. Our results show that 
toxin-producing C. difficile strains, especially our human CRC-associated isolate 
CIm_2663, enhance colon tumor formation in SPF ApcMin∆716/+ mice. In addition, we 
evaluated the spatial localization of C. difficile strains in the infected mouse colons. We 
detected most of C. difficile in the colon lumen with sparse mucus invasion, but C. difficile 
did not aggregate to assemble biofilms in either GF wild-type mice or SPF ApcMin∆716/+ 
mice. The persistent in vivo production of C. difficile toxins, particularly toxin B, correlates 
with mouse colon tumor counts, suggesting that a toxin-dependent mechanism 
contributes to C. difficile-induced colon tumorigenesis. Of note, the colonization of 
toxigenic C. difficile strains induces low-grade chronic inflammation, displaying 
predominant infiltration of macrophages over time in colonic mucosa. Although pro-
oncogenic cytokine IL-17A is similarly upregulated in all tumors regardless of C. difficile 
infection, toxigenic C. difficile strains suppress potential anti-tumorigenic cytokines IFN-γ 
 iii 
and IL-25 in tumors, suggesting C. difficile infection may modify tumor microenvironment, 
at least partly, by shaping inflammatory signatures. Our results support that chronic C. 
difficile toxin exposure predisposes normal colonic epithelial cells to a pro-inflammatory, 
pro-tumorigenic environment that fosters persistent epithelial hyperplasia and sequential 
tumor progression. In summary, toxigenic C. difficile chronic colonization enhances colon 
tumorigenesis in ApcMin∆716/+ mice involving a mechanism dependent on persistent toxin 
B production and host immune responses.  
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Chapter 1  
General Introduction and thesis objectives. 
1.1 General introduction. The mammalian gut microbiota is a complex ecosystem that 
contains trillions of diverse microorganisms predominantly consisting of bacteria in 
addition to viruses and fungi (Bielanski and Haber 2020; Dominguez-Bello et al. 2019). 
The vast majority of these microbial communities inhabit the colon, segregated from the 
colonic epithelium by a protective mucus layer. These symbiotic or, sometimes, dysbiotic 
communities display tremendous interaction with the local mucosal environment and 
guide systemic responses. Thus the gut microbiota is proposed to play an integral role  in 
the host’s nutrition, immunity, metabolism, disease pathogenesis (Lloyd-Price et al. 2016; 
Proctor et al. 2019; The Integrative HMP (iHMP) Research Network Consortium 2016; 
Sears and Garrett 2014) and therapeutic efficacy (Matson et al. 2018; Coutzac et al. 2020).  
 
Human colorectal cancer (CRC) is a multifactorial disease that develops under complex 
conditions involving genetic susceptibility, carcinogens, microbiota and chronic 
inflammation (Sears and Garrett 2014; Garrett 2019; Elinav et al. 2013). CRC risk factors 
such as high-fat diet, smoking, excessive alcohol consumption and obesity significantly 
modify the colonic microbiota (Brenner et al. 2014; Louis et al. 2014; Wu, G. D. et al. 2011) 
that may ultimately drive CRC development (Drewes et al. 2016; Garrett 2019; Chen, J. 
et al. 2017). Some single bacterial species, such as enterotoxigenic Bacteroides fragilis 
(ETBF), pks+ Escherichia coli (E. coli), and Fusobacterium nucleatum (F. nucleatum), 
have garnered attention for their presence in some subsets of human CRC, and their 
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tumorigenic potential in animal models (Wu, S. et al. 2009; Goodwin et al. 2011; Arthur 
et al. 2012; Bullman et al. 2017; Rubinstein et al. 2013). However, none of these bacteria 
are consistently found in all CRC cases, and many more microorganisms relevant to CRC 
likely remain to be identified. Much remains to be learned from translational studies of 
colon tumorigenesis using human fecal (Baxter et al. 2014; Wong et al. 2017; Li et al. 
2019) or mucosal microbiota transferred to murine models (Tomkovich et al. 2019). Only 
recently, the emergence of next generation sequencing technologies, including high-
resolution 16S rRNA gene sequencing and metagenomic technologies, has enabled us 
to appreciate the compelling discoveries of bacterial organization and functional activities 
associated with CRC.  
 
Biofilms are classically defined as bacterial aggregates embedded in an extracellular 
polymeric matrix (Costerton et al. 2003; Swidsinski et al. 2005; Swidsinski et al. 2009; 
Welch et al. 2016). Colonic biofilms are comprised of dense aggregates of diverse 
bacterial species that invade the inner mucus layer (Swidsinski et al. 2005; Dejea et al. 
2014).  For decades, bacterial biofilms have been studied in the context of inflammatory 
bowel diseases where bacterial direct contact with colon epithelial cells likely perturbs 
epithelial function including the barrier properties of the colon epithelium (Swidsinski et al. 
2009; Hall-Stoodley et al. 2004). In 2014, our lab first discovered that biofilms are 
associated with human CRC, predominantly on tumors located in the right or proximal 
colon extending to the hepatic flexure (Dejea et al. 2014). These observations extended 
discussions on how the CRC microbiome impacted CRC biology to a new area. Our 
studies have demonstrated that biofilm-positive (BF+) human colonic mucosa 
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homogenates, either from tumors or non-tumor tissues, reassembled biofilms and 
induced colonic tumors in both germ-free (GF) and specific-pathogen-free (SPF) ApcMin/+ 
(Min: Multiple Intestinal Neoplasia) mice (Tomkovich et al. 2019). ApcMin/+ mice has been 
long used as a murine model to study human CRC including hereditary CRC condition 
known as Familial Adenomatous Polyposis (FAP) that carries germline mutations in APC, 
and sporadic CRC among which somatic mutations in APC can be commonly found in 
about 80% colorectal tumors (Muzny et al. 2012; Rowan et al. 2000; Powell et al. 1992). 
Thus, as above, this mouse model can be used to test mechanisms that promote colon 
tumorigenesis and can help to identify novel bacterial species and virulence factors that 
contribute to colon tumor pathogenesis. 
 
As will be shown in this thesis, 16S rRNA amplicon sequencing of human mucosal 
homogenates combined with detailed murine studies using GF ApcMin∆850/+ and 
ApcMin∆850/+;Il10-/- mice revealed that Clostridioides difficile (C. difficile), detectable in BF+ 
human mucosa homogenates, is remarkedly enriched in the subsequently inoculated GF 
mice, but absent from biofilm negative (BF-) human mucosa homogenates and 
associated mice. The persistent detection of C. difficile 16S rRNA gene sequence along 
with the colon tumor development in the inoculated GF mice raised a critical question 
whether toxigenic C. difficile plays an essential role in colon tumorigenesis. Although 
toxigenic C. difficile is a notorious intestinal pathogen that can result in extensive colitis 
(Chandrasekaran and Lacy 2017; Awad et al. 2015), C. difficile infection had not 
previously been linked to CRC. To date, no dedicated epidemiology studies have 
investigated the association between C. difficile infection and human CRC development 
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(Zheng et al. 2017; Chopra et al. 2010; Burgner et al. 1997), and similarly, very limited 
molecular studies have explored the controversial roles of C. difficile virulence factors in 
pro-tumorigenic signaling (Na et al. 2005; Tao et al. 2016; Chen, P. et al. 2018).  
 
1.2 Thesis hypothesis and objectives. Given our intriguing discovery of C. difficile 
identification in mice that developed tumors after receiving human biofilm microbiota, we 
hypothesized that when persistently colonizing the colon, C. difficile promotes colon tumor 
formation and/or progression. If correct, this may suggest that a subset of individuals 
undergoing C. difficile infection-associated colitis or merely carrying C. difficile 
asymptomatically are at an increased risk of developing CRC over time. The 
mechanism(s) by which C. difficile contributes to the tumorigenic environment are 
unknown. Research is needed to improve understanding about C. difficile pathogenic 
effects in CRC. Herein, we hypothesized that, at least some, C. difficile strains could be 
pro-tumorigenic, acting through C. difficile virulence factors, host immune responses 
and/or microbial dysbiosis. To address the role of C. difficile in colon tumorigenesis, I 
sought to: (a) determine whether C. difficile alone is pro-tumorigenic in ApcMin∆716/+ mice 
and, if so, to characterize in detail the tumorigenesis; (b) identify whether C. difficile toxins 
contribute to colon tumorigenesis; (c) determine if C. difficile induces biofilm formation; 
and (d) assess C. difficile-induced mucosal immune responses that accompany or 
contribute to colon tumor development. 
 
1.3 Thesis approaches. Given that CRC development from initiation to progression 
commonly takes more than 10 years in humans and that longitudinal microbiome 
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information from CRC patients is lacking, we decided to use the genetically tumor-
susceptible mouse model, ApcMin∆716/+ mice to test the capability of C. difficile to induce 
colon tumor formation.  Since prior mouse models of C. difficile infection have focused on 
short-term, predominantly lethal models, our primary goal in this study was to create a 
murine model that allows the sustainable and non-lethal C. difficile colonization for 12 
weeks to permit the testing of colon tumor development. First, we introduced a new 
antibiotic treatment combination to facilitate sustained C. difficile colonization in 
conventional SPF ApcMin∆716/+ mice. Additionally, we optimized a qPCR assay to detect 
the tissue-associated C. difficile copy number from normal colon snips or tumors at 12 
weeks post-inoculation. The localization of C. difficile in the colonic environment was 
visualized using Fluorescence in situ Hybridization (FISH) with a C. difficile species-
specific probe.  
 
Next, we aimed to determine whether C. difficile toxins (toxin A and toxin B) were 
associated with tumor incidence and/or enhanced Wnt/β-catenin signaling activities. To 
determine the role of C. difficile toxins in colon tumorigenesis, we utilized the non-
toxigenic ATCC strain, toxin A-negative and toxin B-negative (A-B-), as a comparator with 
our toxigenic CRC-associated isolate. In parallel, we also inoculated other, non-CRC-
associated toxigenic strains (A+B+ and A+B- mutant derivative) into ApcMin∆716/+ mice with 
the purpose of assessing their capability to induce tumors and addressing whether 
tumorigenic potential is limited to the strain isolated from our BF+ CRC patient. To 
evaluate Wnt/β-catenin signaling activities, the classic tumorigenic signaling in 
ApcMin∆716/+ mice, we measured Wnt downstream target gene expression.  
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Another important objective of this project was to profile the mucosal immune signatures 
induced by C. difficile chronic colonization and their roles in colon tumorigenesis.  
Although studies in diverse mouse models have characterized acute inflammatory 
components in C. difficile colitis, whether human C. difficile colonization in the colon 
provokes chronic inflammation is unknown. To investigate the inflammatory environment 
favoring C. difficile-driven tumorigenesis, the overall mucosal cytokine expression in non-
tumor normal tissues or tumors were measured by qPCR. The immune cell infiltration in 
C. difficile-associated tumor and non-tumor tissues was evaluated by immune-
histochemistry (IHC) targeting multiple immune cell populations.  
 
1.4 Key discoveries. In this thesis project, we addressed the questions: (a) Is C. difficile 
one of the driver species that promote colon biofilm formation and/or tumorigenesis, or 
simply acting as a “passenger” in the tumor-related microbial dysbiosis? (b) Are C. difficile 
toxins and associated mucosal inflammation contributing to the tumorigenic mechanisms? 
In order to investigate the tumorigenic potential and related molecular mechanisms of C. 
difficile strains using ApcMin∆716/+ mice, we successfully modified the antibiotic treatment 
from previously published recipes and established a chronic colonization model of C. 
difficile in SPF ApcMin∆716/+ mice. We found that toxigenic C. difficile strains, particularly 
our human CRC-associated isolate, promote colon tumor incidence after 12 weeks in C. 
difficile-colonized SPF ApcMin∆716/+ mice. The persistent production of C. difficile toxins 
appears to mediate tumor development, in part, by activating the classical Wnt/β-catenin 
signaling pathway but without inducing significant or sustained DNA damage. Although 
neither a C. difficile single-species biofilm nor a polymicrobial biofilm is recapitulated in 
 7 
our mouse models, we demonstrated that C. difficile chronic colonization induces long-
lasting colonic inflammation that correlates with tumor multiplicity. Therefore, this study 
demonstrated that toxigenic C. difficile promotes colon tumorigenesis in ApcMin∆716/+ mice 
through a mechanism likely dependent on long-term C. difficile colonization, persistent 
toxin production and host immune responses.  
 
1.5 Study significance and clinical relevance  
Both CRC and C. difficile infection are critical public health issues that have drawn 
extensive investigations in disease prevention, diagnosis and treatment. This project 
describes the association between C. difficile and the BF+ human CRC subset, and for 
the first time, tests the tumorigenic potential of C. difficile in a murine model. 
 
CRC is the fourth most prevalent cancer worldwide in 2018 (Bray et al. 2018), and 
remains one of the leading causes of cancer-related deaths in both men and women 
despite a significant decline in incidence rates in the United States, particularly in people 
over age 50 years, due to colonoscopy screening (Brenner et al. 2014). Recent 
epidemiological data underscore an increasing CRC risk in the population younger than 
age 50 years (Siegel et al. 2017), and this disturbing trend may be associated with specific 
dietary factors and eating patterns that affect the gut microbiota. Therefore, the 
identification and characterization of new driver bacteria associated with CRC seems 
urgent and critical for advancing our knowledge of how the microbiota modifies CRC 
biology and to devise new approaches to CRC detection and prevention. With these 
objectives, we seek to identify new microbial features to guide colonoscopy screening 
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and the risk stratification for CRC. We thereby hope to contribute to improving clinical    
approaches of prevention, diagnosis, and even treatment of CRC.  
 
Despite advances in diagnostic methods and technology, C. difficile infection (CDI) 
remains a critical health condition in human populations and difficult to cure in some 
patients. CDI has led to many major outbreaks over the past two decades (Warny et al. 
2005; McDonald et al. 2005) due to, in particular, overuse of antibiotics and the 
emergence of C. difficile strains displaying antibiotic-resistance to overused antibiotics. 
C. difficile readily spreads with its production of highly disinfectant-resistant spores that 
foster CDI transmission. High CDI relapse rates of about 20% in CDI patients (Marsh et 
al. 2012; Lessa et al. 2015) and transmission through asymptomatic carriers (Kyne et al. 
2002) present to be challenging clinical problems with CDI. Asymptomatic individuals 
contribute to transmission, whereas whether asymptomatic carriers are at higher risk of 
CDI remains unclear. Biofilm formation may promote latency and a reservoir for C. difficile. 
C. difficile biofilm formation may contribute to asymptomatic carriage with the potential to 
change epithelial biology and could be a reservoir for recurrent CDI. Herein, we sought 
to delineate the tumorigenic potential of C. difficile and its associated mechanisms using 
murine models, with which we hope to provide additional evidence assisting in stratifying 
patients considered for colonoscopy evaluation to advance colon cancer prevention. 
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Chapter 2  
Literature review 
2.1 Microbiota dysbiosis in human colon cancer: evidence of association and 
causality (Chen, J. et al. 2017) 
2.1.1 Epidemiology and etiology of human CRC.  Each year, over 1 million new cases 
of colorectal cancer (CRC) occur, which threaten 551,269 lives equally divided among 
men and women worldwide in 2018 (Bray et al. 2018). In the United States, excluding 
gender-specific cancers, CRC remains the second leading cause of cancer-related 
deaths in men and women despite a significant decline in incidence rates, particularly in 
people over age 50 years, due to colonoscopy screening (Bray et al. 2018; Brenner et al. 
2014). Strikingly, recent epidemiological data demonstrate altered CRC incidence 
patterns in the United States from 1974 to 2013, notably underscoring an increasing CRC 
risk in the population younger than age 50 years (Siegel et al. 2017). This disturbing trend 
calls for new public awareness and research to delineate probable causes of age-specific 
CRC risk, particularly in the young. 
 
CRC often takes more than 10 years to develop due to the accumulation of genetic 
mutations in colonic epithelial cells and sequential progression of the histopathological 
stages including aberrant crypt foci, polyps, adenomas and carcinomas (Fodde et al. 
2001; Brenner et al. 2014). Hereditary forms of CRC only account for 3–5% of all cases, 
while more than 95% of CRC is sporadic and mainly occurs in people older than 50 years 
(Jasperson et al. 2010; Brenner et al. 2014). Besides genetic susceptibility, other risk 
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factors include inflammatory colitis, high consumption of red and processed meat, obesity, 
smoking and excessive alcohol consumption (Brenner et al. 2014; Louis et al. 2014; Wu, 
G. D. et al. 2011; Sonnenburg 2005). Strong evidence suggests these environmental and 
physiological factors significantly modify the colonic microbiota composition and function, 
which has led to increasing interest on the role of the microbiota in colon carcinogenesis 
(Garrett 2019; Goodman and Gardner 2018; Schwabe and Jobin 2013; Sears and Garrett 
2014). 
 
2.1.2 Gut specific pathogens and CRC. Based on our and others’ studies using murine 
models, individual bacterial species provoke colon tumorigenesis by means of both 
microbial factors and host immune responses (Sears and Garrett 2014; Schwabe and 
Jobin 2013; Gagliani et al. 2014). Enterotoxigenic Bacteroides fragilis (ETBF) is common 
in the human microbiota and may be one of the more prevalent pathogens detected in 
human CRC patients. The mechanisms by which ETBF induce murine colon 
tumorigenesis include the induction of reactive oxygen species to directly initiate DNA 
damage, as well as activation of Wnt signaling pathways via E-cadherin cleavage by the 
B. fragilis toxin (BFT) and induction of proinflammatory cytokine IL-17A pathways to 
promote cell survival and proliferation (Wu, S. et al. 2009; Goodwin et al. 2011; Chung et 
al. 2018). Additionally, pks+ Escherichia coli (E. coli) (Arthur et al. 2012; Nougayrède et 
al. 2006) and superoxide-producing Enterococcus fecalis (Huycke et al. 2002) can 
putatively induce tumorigenesis by generating DNA mutagens. One recent study (Long 
et al. 2019) identified that Peptostreptococcus anaerobius (P. anaerobius), a gram-
positive anaerobic bacterium, is enriched in the stools and mucosa of CRC patients, and 
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induced tumors in ApcMin/+ mice. PI3K-Akt-NF-κB signaling mediates P. anaerobius-
induced tumorigenesis by promoting cell proliferation and a pro-inflammatory 
microenvironment. Although the tumorigenic potential of these specific species has been 
studied in-depth with murine models, and each has been found in association with human 
CRC, we still lack an understanding of whether these bacteria or other microbes are 
causal in human CRC cases (Dejea et al. 2014; Kostic et al. 2013; Bullman et al. 2017; 
Garrett 2019).  
 
2.1.3 Gut bacterial dysbiosis in CRC. In addition to the studies focusing on single 
pathogenic species, increasing studies have identified compositional shifts of the gut 
microbiota associated with CRC, which supports the hypothesis that altered microbial 
communities serve as contributors to CRC development (Chen, J. et al. 2017; Drewes et 
al. 2016; Goodman and Gardner 2018; Schwabe and Jobin 2013). For example, several 
studies demonstrate an emergence of putative pathogenic bacteria coincidently with 
substantial commensal depletion in CRC patients (Kostic et al. 2013; Dejea et al. 2014; 
Johnson et al. 2015; Tomkovich et al. 2019). The pro-carcinogenic mechanisms by which 
bacterial dysbiosis contributes to CRC are speculated to reflect microbial-induced 
alterations in host metabolism and mucosal immune responses (Sears and Garrett 2014; 
Louis et al. 2014). However, studies on the gut microbiota profiling in human CRC have 
yielded diverse results regarding the patterns of bacterial communities enriched in tumor 
regions as previously studied (Dejea et al. 2014; Drewes et al. 2017; Bullman et al. 2017; 
Tomkovich et al. 2019). It remains uncertain whether bacterial dysbiosis is merely 















2.1.4 Colonic biofilms in CRC. Bacterial biofilms are complex ecosystems composed of 
polymicrobial aggregates of diverse bacteria embedded in an extracellular polymeric 
matrix, mainly consisting of polysaccharides as well as proteins, nucleic acids and lipids 
(Hall-Stoodley et al. 2004). Colon biofilms are invasive into the dense inner mucus layer 
and directly interact with epithelial cells (Figure 2.1), which has been studied in 
inflammatory bowel disease for decades (Swidsinski et al. 2009). In 2014 our lab reported, 
for the first time, the association between biofilms and human CRC (Dejea et al. 2014), 
and defined that biofilms represent dense bacterial community invasion into the inner 
mucus layer spanning at least a linear distance of 200 μm across the colonic epithelial 
Figure 2.1 Spatial localization of the gut microbiota and bacterial biofilms in the colon. The 
inner mucus layer (light green) lining gut epithelium separates the luminal bacteria from the epithelial 
surface. Colonic biofilms are bacterial communities invasive into the inner mucus layer and in close 
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surface (Swidsinski et al. 2005; Dejea et al. 2014). Colonic biofilms were a nearly 
universal feature of right-sided CRC and their paired normal mucosa obtained from the 
distant edge of surgical resections (Dejea et al. 2014). Interestingly, right colon cancers 
were not uniquely susceptible to biofilm formation. Approximately 17% (Drewes et al. 
2017) of left colon cancers and 13% (15/120) of colonoscopy biopsies collected from 
healthy people at Johns Hopkins Hospital also displayed biofilms. In colonoscopy patients, 
often healthy individuals, the bacterial composition of these biofilms were typically less 
dense and thinner than the exuberant structures on tumors in CRC patients. The colonic 
epithelial cells under the biofilms in the paired normal tissues of CRC patients, or in 
normal colon biopsies obtained from healthy individuals, exhibited reduced or 
redistributed E-cadherin, enhanced IL-6 production, activated Stat3, and increased 
epithelial cell proliferation that are consistent with a pro-oncogenic state (Dejea et al. 
2014).  
 
Colonic biofilms associated with sporadic CRC are all polymicrobial entities (Dejea et al. 
2014; Bullman et al. 2017; Tomkovich et al. 2019). Thus, defining the bacterial 
organization and function of biofilms from CRC patients at the species and/or strain level 
will provide new insights into mechanisms of microbiota-driven CRC. A collaborative 
study (Johnson et al. 2015) demonstrated that bacterial biofilms altered the cancer or 
normal colonic mucosal metabolome via upregulating polyamine metabolism, a possible 
promoter of colonic epithelial proliferation and cancer progression. Biofilm-associated 
enhancement of polyamine metabolites was associated with enriched Clostridial groups 
including Sporobacter, Peptostreptococcaceae and Ceilonellaceae, but reduced 
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Bacteroidales. Recent data from the Sears and Jobin laboratories support that bacterial 
communities in human colonic biofilms are pro-carcinogenic when transferred to mouse 
models (Tomkovich et al. 2019). However, it remains unclear whether some bacterial 
species play a more important role in leading biofilm formation and/or colon tumorigenesis, 
as versus the microbial community as a whole. A clear causal role for any bacterium, 
virulence factor or community structure in human CRC has yet to be well-defined. 
Prospective and longitudinal epidemiological studies are needed to determine the role of 
microbial communities in the initiation and progression of CRC.  
 
2.1.5 Colon-inhabiting oral microbes in CRC. The finding of Fusobacterium in about 
30% or more of CRC cases by 16S rRNA amplicon sequencing (Ahn et al. 2013; Kostic 
et al. 2012; Castellarin et al. 2012) was unexpected and has initiated discussions of an 
association between the oral microbiota and CRC, a topic expanded upon by other 
authors (Vogtmann and Goedert 2016; Flynn et al. 2016; Bullman et al. 2017). The 
Fusobacterium genus, particularly Fusobacterium nucleatum (F. nucleatum), is more 
frequently identified in CRC cases compared with less consistent results in colorectal 
adenoma cases, suggesting that Fusobacterium may contribute to later progression 
instead of earlier initiation of colon carcinogenesis (Ahn et al. 2013; Feng et al. 2015; 
Zackular et al. 2014; Bullman et al. 2017; Garrett 2019). Alternatively, increased, but 
modest, multiplicity of colon adenomas in susceptible mouse models in some, but not all 
experiments, may reflect a capacity of F. nucleatum for tumor initiation or promotion 
(Rubinstein et al. 2013; Yang et al. 2017; Kostic et al. 2013; Tomkovich et al. 2017). F. 
nucleatum appears to utilize several adherence factors such as FadA combined with a 
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proclivity to invade tissue, disrupt cell-cell adhesion, activate Wnt cell proliferation signals 
and stimulate pro-inflammatory pathways to potentially enhance the accumulation of 
genetic mutations or promote colon cancer biology (Rubinstein et al. 2013; Kostic et al. 
2013; Yang et al. 2017). In addition to Fusobacterium, other groups of oral bacteria such 
as Porphyromonas, Peptostreptococcus, Prevotella and Gemella genera are often found 
associated with the colon microbiome of patients with colon cancer (Zackular et al. 2014). 
The carcinogenic potential and virulence factors of these genera are largely unknown. 
Furthermore, it remains to be validated whether these oral microbes detected in the colon 
represent the same species or strains that inhabit the oral cavity. Even if the oral bacteria 
residing in the colon originate from the oral cavity, we do not yet understand the 
mechanisms needed to adapt to the colonic environment and the implications in colon 
carcinogenesis.  
 
2.2 C. difficile Microbiology. C. difficile is a gram-positive, obligate anaerobe that is 
capable of producing spores. The name C. difficile reflects its nature and the difficulty with 
isolation and microbial culture of this microbe. It belongs to the class of Clostridia, the 
family of Clostridiaceae, and the phylum of Firmicutes, and was formerly known as 
Clostridium difficile or Peptoclostridium difficile in Clostridium cluster XI (Ohashi and 
Fujisawa 2019; Galperin et al. 2016; Sandhu and McBride 2018). In 2016, C. difficile 
species was reassigned from Clostridium to the new genus Clostridioides, thus giving it 
the name Clostridioides difficile (Lawson et al. 2016). C. mangenotii is the only other 
species in this new genus.  
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2.2.1 C. difficile chromosome. The C. difficile genome exhibits genetic and phenotypic 
diversity consisting of a single circular chromosome of approximately 4.3 Mbp and a 
plasmid of 7-8 kbp (Sebaihia et al. 2006). Its genome shows only 15% homologous 
sequences with four other clostridial genomes including C. acetobutylicum, C. botulinum, 
C. perfringens and C. tetani, whereas, 50% of sequences are unique to C. difficile species 
(Sebaihia et al. 2006). PCR-ribotyping is one of the common methods used to 
demonstrate the molecular epidemiology of C. difficile strains based on 16S-23S rDNA 
intergenic spacer region patterns. Other molecular typing methods (Killgore et al. 2008) 
for strain characterization include toxinotyping (tcdA/tcdB sequence polymorphisms), 
pulse-field typing and restriction endonuclease analysis typing (whole genome restriction 
pattern polymorphisms), MLST and MLVA (multi-locus repeat- or non-repeat-based 
sequence variations), and SLP typing (surface-protein variations). 
 
2.2.2 C. difficile life cycle. The C. difficile life cycle (Britton and Young 2014) includes 
dynamic changes and genetic regulation during the transformation between two forms of 
this microorganism, spores and vegetative cells (3). C. difficile spores are the primary 
transmission form that survive for long periods with high resistance to heat, aerobic and 
harsh circumstances. The spores inhabit a natural reservoir of soil and feces of domestic 
animals and humans, and any surfaces contaminated with feces. In contrast, C. difficile 
vegetative cells are the outgrowth form with metabolic activity and unable to be sustained 
outside of the host due to sensitivity to an aerobic environment. Once spores are ingested, 
their acid resistance protects their viability from the strong acidic conditions in the 
stomach, and the spores pass through to the colon where they can germinate into  
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vegetative cells in the presence of primary bile acids (Sorg and Sonenshein 2008; 
Howerton et al. 2011; Wilson 1983). The primary bile acids, mainly consisting of cholic 
and chenodeoxycholic acid, are synthesized in the liver, conjugated with taurine or glycine, 
and pass through to the colon (Jones et al. 2008; Chiang 2004). The colonic microbiota 
metabolizes primary bile acids to secondary bile acids, such as lithocholic and 
deoxycholic, that are inhibitory for C. difficile spore germination (Britton and Young 2014; 
Sorg and Sonenshein 2009), thereby suppressing C. difficile colonization. Only when the 
microbial balance is disrupted, mainly by the introduction of antibiotics (Britton and Young 
2014; Buffie et al. 2012; Theriot et al. 2011; Rupnik et al. 2009), does the increased 
Figure 2.2 C. difficile life cycle and pathogenesis in humans. (Adapted from Britton R. A. et al. 2014) 
 
 Toxin A 
 Toxin B 
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availability of favorable nutrients including primary bile acids, amino acids, and 
carbohydrates (Sorg and Sonenshein 2008; Theriot et al. 2014), support C. difficile 
germination, proliferation and toxin production, leading to epithelial damage and 
inflammation (Rupnik et al. 2009; Kachrimanidou and Tsintarakis 2020; Zhu et al. 2018).  
 
2.2.3 C. difficile cultivation and antibiotic resistance. In vitro bacterial culture studies 
revealed 100- to 1000-fold increased C. difficile germination rates when using BHI agar 
plates supplemented with the primary bile acid derivatives such as cholate, taurocholate, 
and glycocholate as vs BHI agar plates alone (Lawley et al. 2009). This observation 
allowed researchers to recover and isolate C. difficile strains from clinical and 
environmental samples (Karen and John 2011). This knowledge is also useful to quantify 
the C. difficile fecal bacterial burden in animal model studies. Environmental spores infect 
mice in a dose-dependent manner and about 7 spores per cm2, which is about 11 spores 
per mouse colon, are needed to infect 50% of the mice (ICD50) (Lawley et al. 2009; Karen 
and John 2011), however, this may vary in a strain-dependent manner. Although C. 
difficile spores are resistant to high temperatures, 70% ethanol and antimicrobials, 
sporicidal agents such as bleach and benzyl chloride can successfully inactivate spores 
and are widely used in laboratory and clinical settings for decontamination. Furthermore, 
C. difficile vegetative cells intrinsically display no response in vitro to multiple antibiotics, 
such as aminoglycosides, tetracyclines, erythromycin, clindamycin, cephalosporins, and 
fluoroquinolones; in addition, clindamycin, cephalosporins, and fluoroquinolones are most 
commonly associated with increased risk of CDI (McDonald et al. 2018; Kelly and LaMont 
2008; Song and Kim 2019; Marsh et al. 2012; Sebaihia et al. 2006). 
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2.3 Current epidemiology studies of CDI  
2.3.1 CDI clinical manifestation, risk factors, and antibiotic treatment. C. difficile was 
first isolated in 1935 from a healthy child (HALL and O’Toole 1935), but was not identified 
to cause antibiotic-associated diarrhea and pseudomembranous colitis until 1978 (1978). 
C. difficile-associated diseases range from mild and self-limiting, watery diarrhea to 
severe bloody diarrhea, toxic megacolon or pseudomembranous colitis, that can be fatal 
(Britton and Young 2014). The risk factors for C. difficile infection include antibiotic 
exposure, advanced age, the use of gastric acid-suppressing drugs, hospitalization and 
host variables like immunodeficiency. Following exposure most often to antibiotics, the 
disrupted fecal microbial composition displays reduced microbiota diversity that 
contributes to the development of CDI (Kachrimanidou and Tsintarakis 2020). In 2011, C. 
difficile infection occurred causing approximately 453,000 cases and threatened 29,000 
lives in the United States (Lessa et al. 2015; Guh et al. 2020). Further, the high recurrence 
rate of CDI after therapy increases the complexity of management and difficulties in 
disease control. Epidemiology studies show that about 20-30% of patients that receive 
CDI antibiotic treatment with metronidazole or oral vancomycin experience a recurrence 
after the treatment is discontinued (Marsh et al. 2012; Kelly and LaMont 2008; Song and 
Kim 2019). While the antibiotic treatment of CDI often cures CDI, the collateral microbiota 
‘damage’ can result in ongoing dysbiosis that renders the host highly susceptible to 
reinfection or relapse. Fidaxomicin, recently added as a first-line CDI therapy (McDonald 
et al. 2018; Guery et al. 2018), is a non-absorbable antibiotic that is less toxic to obligate 
anaerobic commensal bacteria and reduces recurrence for C. difficile strains other than 
ribotype 027 (Abt et al. 2016; Louie et al. 2011). 
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2.3.2 Molecular epidemiology of CDI. With the spread of C. difficile infections worldwide  
during the past two decades, toxigenic C. difficile strains, producing toxin A (gene tcdA) 
and/or toxin B (gene tcdB), continue to be isolated from human hosts (Warny et al. 2005; 
McDonald et al. 2005; Loo et al. 2005). As previously discussed, multiple molecular typing 
methods (Killgore et al. 2008; Vedantam et al. 2012) are commonly used for strain 
identification, including PCR-ribotyping, pulsed-field gel electrophoresis (PFGE), 
restriction endonuclease analysis (REA) of total DNA, and toxinotype. For example, the 
predominant C. difficile strain isolated from the recent CDI epidemic outbreaks in the 
United States, Canada, UK and other European countries, and Asia was strain 
027/NAP1/BI, referred to as ribotype 027, North American pulsed-field type 1 (NAP1), 
and group BI by restriction endonuclease analysis (Voelker 2010). 027/NAP1/BI is a 
hypervirulent strain with toxinotype III that produces higher quantities of toxin A and toxin 
B in vitro and appears to show increased virulence, particularly in outbreak settings. Some 
other well-characterized C. difficile strains prevalent in humans consist of 001/NAP2/J, 
017/NAP9/CF, 078/NAP7/BK , and 106/NAP11/DH (Voelker 2010); all these strains are 
tcdA and tcdB positive except 017/NAP9/CF that is a toxin A⁻, toxin B⁺ strain. Ribotyping 
surveillance data has shown that the molecular epidemiology of the disease is shifting. 
The prevalence of the epidemic ribotype 027 is decreasing globally, while ribotypes 106 
and 017 have become the most common strains in Europe and Asia, respectively 
(Vedantam et al. 2012). The most recent national data provided by the Centers for 
Disease and Control (CDC) shows similar trends in the US, using data derived from 1000 
to 1500 annual samples submitted from ten states, not including Texas (Guh et al. 2020). 
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2.4 Pathogenesis of C. difficile 
2.4.1 C. difficile toxins. C. difficile produces two major large clostridial toxins (LCTs), 
toxin A and toxin B. Both toxins are recognized as C. difficile virulence factors and likely 
contribute to C. difficile-associated disease (Vedantam et al. 2012; Kuehne et al. 2010; 
Chandrasekaran and Lacy 2017). However, strains that produce only toxin B are fully 
virulent in humans; no strains only secreting toxin A are known to cause human disease. 
This observation underpins the use of toxin B detection alone for CDI diagnosis. These 
two large secreted proteins are glucosyltransferases containing four structurally 
homologous domains and have a molecular mass of 308 kDa and 269.6 kDa, respectively 
(Karen and John 2011). The genes encoding toxin A and toxin B, tcdA and tcdB,  
are clustered with three accessory genes tcdR, tcdC, and tcdE and located within the 
19.6 kb pathogenicity locus (PaLoc) (Figure 2.3) (Karen and John 2011). While tcdR and 
tcdC are negative and positive regulators of toxin production respectively, tcdE encodes 
a putative holin and facilitates toxin secretion.  
  
2.4.2 Effects of C. difficile toxins on epithelial cells. The direct effects toxin A and 
toxin B display on epithelial cells can be classified as glucosylation-dependent or -
independent effects. The glucosylation-dependent effects include cytopathic effects that 
Figure 2.3 C. difficile toxin A and toxin B pathogenicity locus (Karen and John 2011). 
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cause cell skeleton disruption and the loss of cell-cell tight junctions, and cytotoxic effects 
comprise cell programmed death, apoptosis (Chandrasekaran and Lacy 2017; Kuehne et 
al. 2010). C. difficile induces apoptosis either through the death receptor-dependent 
extrinsic pathway triggered by toxin A and toxin B or through the mitochondria-dependent 
intrinsic pathway particularly when toxin B is at a lower concentration (Chumbler et al. 
2016). While at higher concentrations (100 pM or above), toxin B initiates the assembly 
of the NADPH oxidase (NOX) complex on endosomes and aberrant production of 
endosomal reactive oxygen species (ROS) (Farrow et al. 2013; Wohlan et al. 2014; 
Chumbler et al. 2016), hereby inducing epithelial necrosis (glucosylation-independent 
cytotoxic effects). The mechanisms operative in vivo are still not clear, but it has been 
proposed that high levels of ROS may promote cellular necrosis through DNA damage, 
lipid peroxidation, protein oxidation and/or mitochondrial dysfunction (Temple et al. 2005; 
Daiber 2010; Prior et al. 2016). It has been suggested that, unlike toxin B, toxin A does 
not enhance ROS production, but causes a glucosylation-dependent apoptosis at all 
concentrations (Chumbler et al. 2016). Indirect effects of toxin A and toxin B on epithelial 
cells have been demonstrated to be mediated by inflammatory factors including cytokines, 
chemokines and reactive oxygen mediators from innate and adaptive immune cells (see 
details in Chapter 3).  
 
2.4.3 Binary toxin. Besides toxin A and toxin B, some C. difficile strains produce a third 
toxin called binary toxin that is termed the C. difficile transferase (CDT) capable of 
catalyzing ADP-ribosylation in host cells. Binary toxin is composed of two unlinked 
proteins, CdtB and CdtA, and encoded on Cdt locus (CdtLoc) separate from the PaLoc 
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(Karen and John 2011). CdtA is the enzymatic component and CdtB has a binding 
function to transport CdtA into target cells (Gerding et al. 2014). These two components 
together cause cytotoxicity leading to cytoskeleton disruption, excessive fluid loss, cell 
rounding, and eventual cell death (Gerding et al. 2014; Cowardin et al. 2016; Berry et al. 
2017). Although highly virulent and epidemic C. difficile strains, such as 027, 078 and 
CD196, also produce binary toxin in addition to toxin A and toxin B  (Awad et al. 2015; 
Metcalf and Scott Weese 2011; Viswanathan et al. 2010), the role of binary toxin in C. 
difficile pathogenicity remains unclear. Some in vitro studies suggest that binary toxin may 
promote C. difficile adherence to Caco-2 cells using cell culture (Schwan et al. 2009). 
However, Metcalf and Weese showed that the biological activities of binary toxin are 
largely unknown in vivo and C. difficile strain production of binary toxin was not associated 
with the severity of C. difficile infection (Metcalf and Scott Weese 2011). Other case 
control studies showed that patients infected with binary toxin-positive strains tended to 
exhibit a higher mortality rate (Bacci et al. 2011), whereas no studies address whether 
binary toxin is causal to increased mortality.  
 
2.4.4 Non-toxin virulence factors. In addition to C. difficile toxins, non-toxin virulence 
factors are increasingly emphasized given potentially important roles in colonization and 
persistence as well as organism proliferation and toxin regulation that are closely 
associated with C. difficile disease pathogenesis. These virulence determinants could 
contribute to the high recurrence rates observed in CDI (e.g., up to 33% in patients 
infected with the recent epidemic strain 027 after a first CDI episode, and 45% after a 
second episode) (Vedantam et al. 2012). Here we provide a current understanding about 
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the non-toxin virulence factors involved in sporulation, flagella, surface proteins, biofilm 
formation and quorum sensing. 
 
Sporulation. Admittedly, spores, as a metabolically dormant form, are not able to 
produce toxins or directly cause epithelial damage leading to disease. A few epidemic 
studies have suggested that the C. difficile strains producing more and resilient spores, 
such as the 027 strain, tend to cause severe disease in CDI patients (Awad et al. 2015; 
Viswanathan et al. 2010). In other words, an increased ability to form spores in the host 
might be associated with higher virulence. However, the efficiency of sporulation in vivo, 
and its contribution to the prevalence of specific C. difficile strains and disease severity, 
is still an open question. The downstream regulators, and signaling molecules of Spo0A 
(Vedantam et al. 2012), a master regulator of sporulation, are highly conserved in Bacillus 
spp. and clostridia, however, the upstream factors influencing the sporulation checkpoint 
and the corresponding signaling pathways remain to be studied for clostridia. 
 
Flagella. Flagella are filamentous organelles that drive cell movement and can play a 
significant role in some bacterial species for host invasion and colonization. For instance, 
Helicobacter pylori flagella are critical to its adherence and colonization (Bergonzelli et al. 
2006; Dunne et al. 2014). Likewise, flagella allow C. difficile to be motile and pass through 
the mucus layer to initiate adherence to the epithelial cells (Stevenson et al. 2015; 
Tasteyre et al. 2001). FliC, the major flagellin structural monomer, and FliD, the cap 
protein are two major C. difficile flagellar proteins that have been well characterized 
(Tasteyre et al. 2001). Not all pathogenic C. difficile strains show a flagellated phenotype 
by electron microscopy, but the flagellin gene universally exists in the C. difficile genome 
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(Tasteyre et al. 2000). The role of flagella in CDI pathogenesis is contentious and appears 
to be strain dependent. Studies with stain R20291 (ribotype 027) showed that C. difficile 
flagella promoted adherence to cells and intestinal tissue (Baban et al. 2013), whereas, 
absence of flagella in strain 630∆erm did not reduce adherence (Tasteyre et al. 2001; 
Baban et al. 2013).  
 
 
Surface proteins. S-layers are surface-exposed proteinaceous layers coating the 
bacterial cell surface. S-layer proteins (SLPs) are the most well-characterized family of C. 
difficile cell wall proteins (CWPs). SLPs and CWPs have been proposed as putative 
virulence factors and may play a role in C. difficile adherence and colonization on the 
colon epithelium.  C. difficile SLPs are derived from the polypeptide precursor, SlpA, by 
proteolytic cleavage by the protease Cwp84 (Dang et al. 2010). Cwp84 is the best studied 
cell wall protein and a cysteine protease involved in processing the S-layer (la Riva, de 
et al. 2011). Cwp84 has also been shown to degrade extracellular matrix proteins in vitro, 
suggesting that this protein may play a role in tissue degradation and bacterial 
dissemination during infection (Janoir et al. 2007). 
 
Biofilm formation and quorum sensing. Evidence regarding C. difficile biofilm 
formation remains insufficient as studies only suggest C. difficile may form biofilms in vitro 
but not in vivo. Nevertheless, key questions remain regarding the mechanisms by which 
C. difficile accomplish biofilm assembly and whether biofilms enhance C. difficile 
persistence and virulence in hosts. C. difficile R20291 was demonstrated to yield more 
biofilms in vitro compared to C. difficile 630 (Dapa and Unnikrishnan 2013), suggesting 
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C. difficile capability for biofilm formation varies between strains. Cwp84 and LuxS are 
virulence-associated proteins that promote C. difficile biofilm formation 
(Soavelomandroso et al. 2017; Dapa and Unnikrishnan 2013; Dapa et al. 2013). Quorum 
sensing, a form of bacterial cell-cell communication, plays a key role in C. difficile biofilm 
formation in early and late stationary phases when the bacteria start to produce 
extracellular matrix composed of proteins, polysaccharide and DNA. In this process, the 
LuxS protein is a putative regulator affecting both biofilm assembly and biological 
activities within the biofilm microbial community (Dapa and Unnikrishnan 2013).  
 
2.5 Animal models of CDI and colon tumorigenesis in ApcMin/+ mouse model  
2.5.1 Animal models of CDI. Various animal models have been developed to study C. 
difficile infection and disease pathogenesis, such as hamster, mouse, rat, rabbit, infant 
pig and so on (Hutton et al. 2014; Best et al. 2012; Lawley and Young 2013). Until recently, 
hamsters were most commonly used for modeling C. difficile infection. The hamster 
model has an integral role in studying C. difficile pathogenesis (Best et al. 2012) as 
pathological signs observed in a hamster after infection mirror many clinical manifestation 
of human CDI (Bartlett et al. 1977; Price et al. 1979). Hamsters were employed as 
important tools to assess the role of C. difficile toxins by comparing the infection severity 
of isogenic C. difficile mutants (Lyras et al. 2009; Kuehne et al. 2010; Kuehne et al. 2014). 
However, murine models have become increasingly popular and important in unravelling 
diverse aspects of CDI including colonization, host susceptibility, disease 
pathophysiology and recurrence (Hutton et al. 2014; Lawley and Young 2013). Mouse 
models of CDI have been continuously improving and are now extensively used because 
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infection susceptibility, similar to humans, can be induced by various antibiotics and 
mouse-specific reagents allowed better analysis of host tissues. Similar to human CDI, 
mouse susceptibility must be induced by disrupting the microbiota through antibiotic 
treatment. The effect of antibiotics on the microbiota and the role of commensal 
organisms in colonization resistance to CDI have been reviewed in detail elsewhere 
(Adamu and Lawley. 2013). Readily available mouse models of CDI include 
gnotobiotic/germ-free mice (Pawlowski et al. 2010; Reeves et al. 2012), SPF mice 
undergoing an antibiotic cocktail therapy to disrupt the normal gut flora (Chen, X. et al. 
2008; Buonomo et al. 2016; Abt et al. 2015) and, most recently, single antibiotic pre-
treatment to induce susceptibility to CDI (Buffie et al. 2012; Theriot et al. 2014). 
 
2.5.2 Colon tumorigenesis in ApcMin/+ mouse model. Human CRC development is 
classified as involving at least four crucial genetic changes targeting three tumor-
suppressor genes APC, SMAD4 and TP53 and one oncogene KRAS; these genes are 
thought to dominate the evolutionary process of CRC histopathological sequences 
(Fodde et al. 2001). The APC gene is the primary checkpoint for the initiation of epithelial 
transformation that leads to the formation of aberrant crypt foci (ACF), the very earliest 
neoplasia (Powell 1992). The tumor suppressor protein encoded by the APC gene 
regulates the nuclear translocation of β-catenin, an important transcriptional co-activator 
in the Wnt signaling pathway (MacDonald et al. 2009). Earlier studies have shown that 
Wnt signaling is commonly activated in colon cancers (Deitrick and Pruitt 2016). The loss 
of wild-type APC functions, resulting typically from loss of or mutation of the APC genes 
on both alleles, is needed to activate Wnt/β-catenin signaling and promote the 
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transcription of target genes involved in cell proliferation, anti-apoptosis, and 
angiogenesis (Fodde et al. 2001; Deitrick and Pruitt 2016). APC gene mutations occur in 
more than 70% of the patients with colon adenomas, so that the APC gene is regarded 
as the most common gene responsible for CRC (Brenner et al. 2014). Heterozygous 
ApcMin/+ mice develop multiple colon tumors at 8-12 weeks after ETBF colonization, but 
sham ApcMin/+ mice display typically zero to few colon tumors. In the ApcMin/+ mouse model 
used in our lab, called ApcMin∆716/+, the Apc gene is heterozygous for a truncation at codon 
716 of the Apc gene. While many Apc gene mutation models exist (Colnot et al. 2004; 
Hinoi et al. 2007), this model displays a modest increase in colon tumors at baseline 
compared to other ApcMin/+ mouse models. The ApcMin/+ mouse model is classically 
considered as a colon cancer model, although most tumors occur in the small intestine 
unless the mouse is colonized by a currently recognized pro-oncogenic bacterium such 
as ETBF. Thus, ApcMin/+ mice at baseline poorly replicate human disease because 
intestinal polyposis is largely limited to the small intestine (Hinoi et al. 2007). 
 
2.6 C. difficile and human colon cancer. The notoriety of C. difficile infection has 
escalated in recent years due to the epidemic of strain 027 worldwide, increased disease 
incidence and severity, and high CDI recurrence rates (Warny et al. 2005). As stated 
earlier, CDI commonly results in mild to severe colitis and may precipitate inflammatory 
bowel disease (Viswanathan et al. 2010; Kirby 2011; Abt et al. 2016). Although 
inflammation- or colitis-associated colon cancer has been extensively studied, a 
connection between C. difficile-induced colitis and colon cancer has not been proposed. 




To date, we lack epidemiology studies designed to study the association between C. 
difficile colonization/infection and CRC development. Our literature search identified 
interesting findings described in two recent human CRC studies; namely, that a high 
occurrence of Fusobacterium (most are F. nucleatum) and C. difficile exists in CRC 
patients (Bullman et al. 2017; Fukugaiti et al. 2015). However, these two studies only 
analyzed 10-20 patients each and whether C. difficile colonization is identified in CRC 
patients requires using a bigger CRC database and additional human studies. It is also 
possible that C. difficile detection belongs to a subgroup of CRC patients not yet identified 
and in need of characterization. Previous studies indicate that cancer patients on 
chemotherapies, not limited to colorectal cancer, exhibit an increased risk of CDI thought 
to be due to their immunocompromised status, chemotherapy and/or antibiotic exposure 
compared with non-cancer patients (McDonald et al. 2018; Chopra et al. 2010). Some 
studies report that 19% of patients were colonized with toxigenic C. difficile on admission 
to oncology wards, and 16.1% of 205 preoperative CRC patients were positive for C. 
difficile predominantly (97%) toxigenic isolates (Zheng et al. 2017). Whether CRC patients 
who are immunocompromised are more susceptible to CDI or C. difficile colonization that 
contributes to the progression of human CRC remains to be determined. For initiation of 
CRC, it would likely be necessary for a patient to be colonized with C. difficile for many 
years; however, long-standing longitudinal studies of C. difficile colonization in humans 
are not available. 
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Initial molecular studies suggest that the mechanism(s) of the association between toxin 
B and tumorigenesis are controversial. On one hand, toxin B might promote 
tumorigenesis through EGFR signaling pathway as an earlier study found that toxin B 
activates the epidermal growth factor receptor (EGFR)-ERK-MAP signaling pathway in 
human colonic epithelial cells (Na et al. 2005), which has long been associated with a 
number of cancers including CRC. Notably, EGFR overexpression has been reported to 
occur in 60%-80% of human CRCs and is associated with a poor prognosis.  On the other 
hand, recent studies suggest that toxin B competes with activators of Wnt protein 
receptors to block Wnt/β -catenin signaling activity (Tao et al. 2016; Chen, P. et al. 2018), 
indicating toxin B might have an antitumor effect. Whether C. difficile toxin B affects colon 
tumorigenesis in vivo needs additional study. 
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Chapter 3    
C. difficile strain isolated from human CRC tumor 
mucosa enhances tumor formation in chronically 
colonized SPF ApcMin∆716/+ mice 
3.1 Abstract 
As a notorious gut infectious agent, C. difficile infection is the leading cause of antibiotic-
associated diarrhea and has been a focus of nosocomial, antibiotic-associated acute 
colitis research. However, current studies have rarely connected C. difficile infection with 
chronic colitis and/or related chronic pathogenesis. C. difficile infection as a risk for colon 
cancer development is a new and novel research area. Previous work of the Sears 
laboratory demonstrated that human mucosal biofilm homogenates induce colon tumor 
formation after inoculation into GF ApcMin∆850/+ or ApcMin∆850/+;Il10-/- mice. In this study, we 
identified that C. difficile is present in some human colonic biofilms that enhanced 
tumorigenesis in GF ApcMin∆850/+ or ApcMin∆850/+;Il10-/- mice. Herein, we demonstrated that 
toxigenic C. difficile strains (particularly the CRC-associated isolate), but not a non-
toxigenic strain, promote colon tumorigenesis in SPF ApcMin∆716/+ mice at 12 weeks after 
colonization. We further showed that C. difficile strains demonstrating persistent toxin 
production in vivo are more potent in enhancing tumor formation. Although small numbers 
of C. difficile were detected by FISH in the inner mucus layer of the colonized mouse 
colons, a densely packed bacterial biofilm is not assembled at 2 weeks after colonization 
in both GF wild-type mice and SPF ApcMin∆716/+ mice. Additionally, C. difficile spatial 
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localization in the colon is not restricted to the tumor microenvironment and, thus, chronic 
colonization with C. difficile and its associated chronic mucosal inflammation is proposed 
as a possible risk factor for colon tumorigenesis in humans.   
 
3.2 Introduction  
Despite advances in clinical medicine and diagnostic methods, C. difficile infection 
remains the leading cause of antibiotic-associated colitis and causes about half a million 
cases each year in the United States (Lessa et al. 2015). Risk factors for CDI include 
antibiotic exposure, advanced age, the use of gastric acid-suppressing drugs, 
hospitalization and host variables like immunodeficiency (Chopra et al. 2010; Rupnik et 
al. 2009). C. difficile-induced colitis became a surging public health problem due to 
increased disease severity associated with select C. difficile strains and several major 
CDI outbreaks over the past two decades (Warny et al. 2005; McDonald et al. 2018;). 
Compelling progress has been gained in studying CDI pathogenesis, however, current 
research mainly focuses on the acute onset of colitis or association with inflammatory 
bowel disease in both human populations (Marsh et al. 2012; Galdys et al. 2014) and 
animal models (Theriot et al. 2014; Buonomo and Petri 2016; Abt et al. 2015).  
 
CDI recurrence is a challenging clinical problem as up to 35% of CDI patients experience 
a recurrence within 8 weeks of a previous episode (Marsh et al. 2012; Song and Kim 
2019). As a spore-forming bacterium, C. difficile is highly resistant to common 
disinfectants (Sebaihia et al. 2006). Further, antibiotics such as metronidazole, 
fidaxomicin or vancomycin after treatment of at least 10 days may still fail to cure the 
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disease, in part, because these antibiotics are inactive against the C. difficile spore form. 
However, antibiotic treatment contributes to ongoing fecal ‘dysbiosis’ that renders patients 
at a higher risk of recurrent CDI due to relapse of infection with the same strain or 
reinfection by acquisition of a different C. difficile strain (Song and Kim 2019). It is 
hypothesized that recurrence may be, at least in part, due to the spore-forming ability 
and/or further persistence in a colon mucosal biofilm that may provide C. difficile with an 
environment in which resistance to antibiotics and avoidance of host immune responses 
occurs (Galdys et al. 2014). The ability of C. difficile to form a single species biofilm or 
polymicrobial biofilms in vitro (Soavelomandroso et al. 2017) has been reported since 
2012 (Soavelomandroso et al. 2017; Dapa and Unnikrishnan 2013; Dapa et al. 2013), 
however very little is known about C. difficile biofilm formation in vivo and its impact on 
epithelial biology. Whether CDI recurrence is associated with or results in chronic colitis-
associated diseases including colorectal cancer remains unclear. 
 
CDI has been very rarely connected to colon cancer development although limited data 
suggest cancer patients tend to have a higher risk of C. difficile colonization or infection. 
A few earlier clinical studies suggest that about 20% cancer patients are positive for C. 
difficile predominantly with toxigenic isolates (Zheng et al. 2017; Chopra et al. 2010; 
Burgner et al. 1997). Whether CRC patients who are immunocompromised are more 
susceptible to CDI or whether C. difficile colonization precedes and contributes to the 
initiation and/or progression of human CRC remains unclear. Recently, Bullman’s RNA-
Seq analysis (Bullman et al. 2017) with paired CRC primary tumors and liver metastases 
identified C. difficile sequences in 8 of 10 CRC patients; most cases were also associated 
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with Fusobacterium. This study is restricted by the limited patient number enrolled and, 
further, did not validate the C. difficile detection such as with targeted qPCR or 
microbiology culture. A population-based epidemiology study is needed to inform the 
association between C. difficile and CRC, and to characterize the clinical and molecular 
features of the CRC subset in which C. difficile is detected including the prior historical 
context (such as having been diagnosed with CDI). 
 
A previous study in our lab (Dejea et al. 2014) identified mucus-invasive bacterial biofilms 
in the  human colonic mucosa including tumor mucosa, paired normal mucosa from the 
edge of the surgical resections and colonoscopy biopsies from healthy individuals. When 
inoculated into GF ApcMin∆850/+ or ApcMin∆850/+;Il10-/- mice and SPF ApcMin∆716/+ mice, 
homogenates of each type of biofilm positive (BF+) mucosa enhanced colon 
carcinogenesis and colonic biofilm assembly as compared with biofilm negative (BF-) 
biopsies (Tomkovich et al. 2019). Using 16S rRNA amplicon sequencing, we identified C. 
difficile in BF+ human inocula as well as stools and colons from mice inoculated with the 
human BF+ inocula in which C. difficile was detected, but not in mice inoculated with BF- 
mucosa homogenate (Fig. 1A).  These results led us to ask whether C. difficile is a driver 
species in the biofilm microbiota that is carcinogenic and bacterial biofilm-promoting in 
ApcMin/+ mouse models. Herein, this study will shed light on the mechanisms and role of 
C. difficile in BF+ human CRC development.  
 
In this project, we hypothesized that C. difficile colonization promotes a pro-carcinogenic 
environment in the colons of ApcMin/+ mice. To test this hypothesis, we developed a new 
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sustainable and non-lethal mouse model for C. difficile chronic colonization using SPF 
ApcMin∆716/+ mice. We further tested the capability of C. difficile to assemble single-species 
biofilms in GF wild-type C57BL/6J mouse colons or polymicrobial species biofilms in SPF 
ApcMin∆716/+ C57BL/6J mouse colons.  
 
3.3 Material and Methods 
3.3.1 DNA extraction and 16S rRNA amplicon sequencing. These methods have been 
described in a previous publication (Tomkovich et al. 2019). In brief, DNA was extracted 
from human mucosal homogenates, mouse feces (collected at week 1 and week 12) and 
distal colon tissue snips (week 12) from colonized GF ApcMin∆850/+ and ApcMin∆850/+;Il10-/- 
mice using phenol/chloroform separation followed by DNeasy Blood & Tissue Kit 
(QIAGEN). To construct DNA libraries for 16S rRNA amplicon sequencing, we targeted 
the V1–V3 hypervariable region of 16S rRNA gene for PCR amplification using primers 
27F (5′-AGAGTTTGATCCTGGCTCAG-3′) and 534R (5′-ATTACCGCGGCTGCTG G-3′). 
The primer pairs are labeled with universal Illumina paired-end adapter sequences and 
unique barcodes of 4 to 6 nucleotides to identify individual targets in multiplex sequencing. 
PCR amplicons were purified using the Agencourt AMPure XP Kit (Beckman Coulter Inc.) 
and quantified with the KAPA Library Quantification Kit (KAPA Biosystems) (Tomkovich 
et al. 2019). Samples were pooled in equimolar amounts and sequenced on an Illumina 
MiSeq according to the manufacturer’s specifications. 16S rRNA sequences are available 
in the NCBI’s Sequence Read Archive (SRA PRJNA423288).16S rRNA-Seq data were 
analyzed by Dr. James White using the Resphera Insight high-resolution protocol 
(Drewes et al. 2017; Tomkovich et al. 2019). Samples with more than 14,000 high-quality 
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sequences were randomly subsampled to 14,000 per sample. Relative abundance 
estimates are based on the subsampled dataset. High-quality passing sequences were 
assigned to a taxonomic lineage using the Resphera Insight method that has been 
optimized to ascribe corresponding sequences to species level membership. Single 
species assignments are designed to be of diagnostic confidence in quality.  
 
3.3.2 C. difficile human strain isolation. As stated in 3.3.1, human biofilm microbiota 
were transferred to GF ApcMin∆850/+ or ApcMin∆850/+;Il10-/- mice and the microbial 
composition in mouse feces was profiled using 16S rRNA amplicon sequencing. Based 
on its comparatively high C. difficile relative abundance, we picked week 1 stool from 
mouse #2663 for further analysis. The frozen mouse stool (-80℃) was first homogenized 
anaerobically in CCMB-TAL medium (Cycloserine Cefoxitin Mannitol Broth with 
Taurocholate Lysozyme Cysteine, Anaerobe Systems) that is predicted to help C. difficile 
spores recover and support germination. After 48 hours, turbidity and a visible color 
change of CCMB-TAL medium from pink to yellow indicated spore germination and C. 
difficile growth. Next, the suggestive CCMB-TAL broth was streaked on CCFA-HT agar 
plates (Cycloserine Cefoxitin Fructose Agar with Horse Blood and Taurocholate, 
Anaerobe Systems). Single colonies grown on CCFA-HT plates were genotyped by 
colony qPCR performed on QuantStudio 5 Real-Time PCR Systems (Thermo Fisher) 
with primers targeting the C. difficile species-specific 16S rRNA gene region as well as 
tcdA and tcdB genes (Table 1). The C. difficile 16S rRNA gene was amplified in a qPCR 




Gene Expression Master Mix (Thermo Fisher), and bacterial DNA using the following 
conditions: 95℃ for 10 min and 40 cycles of 95℃ for 30s and 58℃ for 60s. tcdA and tcdB 
genes were detected using a qPCR reaction of 0.4 μM primers, 1x Fast SYBR® Green 
Master Mix, and bacterial DNA under the conditions: 95℃ for 20 min and 40 cycles of 95℃ 
for 3s and 58℃ for 30 s.   
 
3.3.3 C. difficile strains and spore preparation. C. difficile strains used in this study are 
summarized in Table 3 and the toxin genes were typed by qPCR using the primers in 
Table 1. The toxigenic strain ATCC 9689 and non-toxigenic strain ATCC 700057 were 
kindly provided by the Clinical Microbiology Laboratory of The Johns Hopkins Hospital. 
The ribotyping of CRC-associated isolate CIm_2663 was performed by Dr. Seth Walk at 
Montana state University by fluorescent PCR ribotyping as previously detailed (Walk et 
al. 2012). The whole genomes of C. difficile strains including ATCC 700057, and 
CIm_2663 (human strain passed through GF mouse gut) were sequenced by The CHOP 
Microbiome Program at University of Pennsylvania and analyzed by Dr. James White in 
alignment with whole genome sequences of a few reference strains available in NCBI’s 
database including strain ATCC 9689 which is also included in this study. 
Table 1. C. difficile primers and probes used in this study 
C. difficile 16s rRNA-forward TTGAGCGATTTACTTCGGTAAAGA 
(Rinttilä et al. 2004) 
C. difficile 16s rRNA-reverse CCATCCTGTACTGGCTCACCT 
C. difficile probe 
16S_probe_TAMRA_lBRQ  TAACGCGTGGGTAACCTACCCTGTA 
Designed for this 
study using IDT tool 
 
C. difficile tcdA-forward-qPCR GTCGGATTGCAAGTAATTGACAATA 
(Lyras et al. 2009) 
C. difficile tcdA-reverse-qPCR TAACAGTCTGCCAACCTTTTGAGA 
C. difficile tcdB-forward-qPCR ACCATATAGCTTTGTAGATAGTGAAGGAAA 
C. difficile tcdB-reverse-qPCR AAGAACTACATCAGGTAATTCAGATACAAA 
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For spore preparation, C. difficile strains were plated to a lawn on reduced BHI (Brain 
Heart Infusion Powder, Becton Dickinson) plates and cultured anaerobically for 5 to 8 
days at 37°C to induce sporulation. Colonies were collected in 1-2 ml sterile phosphate- 
buffered saline (PBS) and incubated at 60°C for 1 hour to kill the vegetative cells. Spores 
were washed 3 times with PBS, and viable spores were enumerated as colony-forming 
units (CFUs)/ml by plating serial dilutions on CCFA-HT plates or BHI-T (BHI agar 
supplemented with 0.1% taurocholate (Sigma)) plates. 
 
3.3.4 Mouse breeding and housing. The male ApcMin∆716/+ C57BL/6J mice (6-week- to 
6-month-old, in-house breeding colony) and female wild-type C57BL/6J mice (6-week- to 
9-month-old, Stock No. 000664, Jackson laboratories) were housed and bred with 
autoclaved food, bedding and chlorinated water in the specific-pathogen-free (SPF) 
facility in the Cancer Research Building II at Johns Hopkins University. Germ-free (GF) 
C57BL/6J wild-type mice were housed and bred in flexible film isolators with sterile water, 
diet, bedding and filtered air in the Germfree Mouse Core Facility (under SOP SP20M233 
protocol) at Johns Hopkins University. All animal procedures were performed in 
accordance with the NIH guidelines for housing and care of laboratory animals and were 
approved by the Johns Hopkins University Animal Care and Exposure Committee (under 
protocol MO20M85).  
 
3.3.5 Mouse experiment SPF ApcMin∆716/+ mice, 6- to 10-week-old, both male and female, 
were given vancomycin (Sigma) (0.05 mg/ml) and gentamicin (Sigma) (0.035 mg/ml) in 
drinking water for 5-7 days (range from 3 to 5 days in pilot studies) followed by 2-3 days 
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of regular drinking water prior to the inoculation of 106 C. difficile spores (range from 103 
to 106 in pilot studies) in PBS or PBS alone for sham mice via oral gavage. Gentamicin 
(0.035 mg/ml) supplement in the drinking water was resumed after inoculation and 
continued throughout 3 months of the experiment duration. Germ-free wild-type mice, 10- 
to 12-week-old, both male and female, were inoculated with 104 C. difficile spores in PBS. 
We monitored signs of illness or disease including survival, body weight loss, diarrhea, 
bloody stools and hunched posture. To avoid cross-contamination, sham germ-free wild-
type mice were kept in isolators until necropsy. 
 
The level of C. difficile colonization in experimental mice was evaluated from fecal 
samples as follows. In the first few pilot experiments, we extracted DNA from week 4 
and/or week 12 stools using Quick-DNA Fecal/Soil Microbe DNA Miniprep Kit (Zymo 
Research) and quantified C. difficile copy numbers by qPCR with C. difficile 16S rRNA 
primers and probe as described above. In subsequent experiments, longitudinal C. 
difficile bacterial burden was determined by both qPCR (at week 1, week 4 and week 12 
after colonization) and microbial culture (at week 1, week 4, week 8 and week12 after 
colonization). To cultivate C. difficile from mouse stools, ～0.02-0.10 g stool samples (1 
g/ml, e.g., 0.1 g stool = 0.1 ml) were suspended in sterile and preconditioned PBS (9 parts 
of stool volume, e.g., 0.9 ml for 0.1 g stool) in an anaerobic chamber. Stool homogenates 
were heated at 60°C for 1-2 hour to remove vegetative cells and serially diluted for C. 
difficile enumeration (CFUs/g stool) on CCFA-HT or BHIS-T (BHI agar supplemented with 
Clostridium difficile Supplement (Sigma) and 0.1% taurocholate) plates. 
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3.3.6 Colon harvest and tumor assessment. Mice were necropsied at 12 or 13 weeks 
after inoculation. Colons were flushed with sterile PBS and cut open longitudinally to 
grossly examine colonic tumors. For mucosal cytokine analysis, a piece of middle colon 
(about 0.5 cm), free of visible tumors, was flash-frozen in liquid nitrogen. The remaining 
colon was fixed in 10% neutral buffered formalin solution overnight followed by methylene 
blue staining. Colonic tumors were hereby visualized as dark blue and quantified under 
the Leica ES2 Stereo Microscope by one or two experienced experts separately (S.W. or 
C.L.S.). For histopathology, the colons were Swiss-rolled for paraffin-embedding, 
sectioning (4 μm) and Hematoxylin and Eosin (H&E) staining by Oncology Tissue 
Services (OTS) Core Facility at the Johns Hopkins University. Histological scoring of 
inflammation, epithelial damage, hyper-proliferation and microadenoma quantification 
was performed blindly by S.W. 
 
3.3.7 Tissue RNA extraction, cDNA synthesis, and RT-qPCR. Total RNA from 0.5 cm 
normal middle colon tissue was extracted using the Direct-ZolTM RNA Miniprep kit (Zymo 
Research) following the protocol. In brief, flash-frozen tissue snips were thawed to room 
temperature in RNase and DNase free tubes containing TRIzol® and 2 mm Zirconia-
Silicate beads and then homogenized by bead beating at 3800 rpm for 2 min. Tissue 
homogenates were centrifuged at 4°C, 10,000 g for 5 min to remove tissue debris.  Total 
RNA was purified from the clarified homogenates by passing through a Zymo-Spin 
Column and RNA binding column sequentially with wash and elution buffers, and the RNA 
concentration was measured by a NanoDrop Spectrophotometer (Thermo Scientific). 
Then, we used 500ng or 1µg of RNA for cDNA reverse transcription using the High-
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Capacity RNA-to-cDNA Kit (Thermo Scientific). The target genes evaluated by the 
TaqMan™ Gene Expression Assay (FAM) are listed in Table 5. The relative mRNA 
quantities were expressed using a standard ∆∆CT method that calculated fold-changes 
and were normalized to mouse GAPDH, a housekeeping gene.  
 
3.3.8 Fluorescence in situ hybridization (FISH) and confocal microscopy. The distal  
3 cm of colons with fecal content from SPF ApcMin∆716/+ and GF wild-type mice were 
immediately fixed in Carnoy’s solution (60% methanol, 30% acetic acid, and 10% 
chloroform) and followed by paraffin-embedding, and sectioning (4 μm) in the OTS core 
facility as described above. Bacterial spatial localization and/or biofilm formation was 
visualized on colon sections by FISH with the EUB338 universal bacterial probe (5’- 
GCTGCCTCCCGTAGGAGT-3’) and C. difficile species-specific probe (5’-
CATCCTGTACTGGCTCAC-3’) contrasted with nuclear counterstain, 4′,6-diamidino-2-
phenylindole (DAPI). In brief, unstained colon slides were deparaffinized through baking 
at 50°C for 10 min and 2 dips in xylene followed by re-hydration through an ethanol serial 
gradient. 0.5 ng/μl pre-mixed bacterial probes in hybridization buffer containing 20 mM 
Tris-HCl, 0.9 M NaCl, 0.01% sodium dodecyl sulfate were applied to the slides and then 
incubated in a dark humidified chamber at 46°C for 1.5 hours. The hybridized slides were 
covered with ProLong Gold® Antifade Mountant (Cell Signaling Technology) and stored 
in the dark at room temperature prior to confocal microscopy. Confocal microscopy (Zeiss 
LSM880) was conducted in the Microscope Core Facility at Johns Hopkins School of 
Medicine, and images were analyzed by ImageJ (NIH). Bacterial biofilms on Carnoy’s 
fixed mouse colonic tissues were defined as a dense bacterial community invading the 
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inner mucus layer (within 1 μm of the epithelium) for at least 200 μm of the epithelial 
surface (Dejea et al. 2014; Tomkovich et al. 2019). 
 
3.3.9 Periodic Acid-Schiff (PAS) stain. Following the protocol of the PAS Stain Kit 
(Sigma-Aldrich), we stained the distal 3 cm colon sections to assess mucus presence in 
parallel with successive sections hybridized with FISH bacterial probes. In brief, colon 
slides were deparaffinized and re-hydrated as stated in the FISH procedure (Material and 
Method 3.3.8). Then, the slides were sequentially immersed in 1% Periodic Acid Solution 
for 10 min and Schiff’s Reagent for 40 min with rinse steps in distilled water after each 
stain. Hematoxylin Solution (Mayer’s, Modified) was used for nuclear counterstaining.  
 
3.3.10 Statistical Analysis. Statistical analysis was conducted with GraphPad Prism 
software version 7.0. Numerical data without a normal distribution were expressed as 
means ± SE, and differences between two groups were evaluated using the 
nonparametric Mann-Whitney U test. For multiple group comparisons, statistical analysis 
was performed with nonparametric Kruskai-Wallis test followed by the uncorrected 
Dunn’s test for each two-group comparison because we considered each experimental 




3.4.1 Detection, isolation and characterization of a C. difficile strain from human 
biofilm-positive tissue and subsequently inoculated mice. Our previous translational 
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study (Tomkovich et al. 2019) that transferred human mucosal homogenates to GF 
ApcMin∆850/+ or ApcMin∆850/+;Il10-/- mice was conducted in collaboration with the laboratory 
of Dr. Christian Jobin at the University of Florida. In brief, GF ApcMin∆850/+ or 
ApcMin∆850/+;Il10-/- mice were inoculated with 4 types of human colonic mucosal 
homogenates: biofilm-positive tumors (BF+T) and biofilm-positive paired normal tissues 
(BF+NF) from the surgical resections of 5 CRC patients or histologically normal biofilm-
positive biopsies (BF+bx) or biofilm-negative (BF-bx) biopsies from 5 healthy individuals 
who underwent screening colonoscopy. After inoculation, mouse fecal pellets were 
collected at week 1 and week 12.  Colon snips were flash-frozen at week 12 during the 
mouse harvest. The microbial composition in the human inocula and the subsequently 
inoculated mouse feces (at week 1 and week 12) and flash-frozen mouse colon mucosa 
(at week 12) were profiled using 16s rRNA amplicon sequencing as detailed in Materials 
and Methods 3.3.1. Unexpectedly, we identified C. difficile sequences in mice inoculated 
with biofilm-positive human mucosal homogenates, but not in mice inoculated with a 
biofilm-negative human mucosal homogenate (Figure 3.1). The C. difficile relative 
abundance was selectively enriched in mouse stools and colonic tissues as compared to 
the human colonic mucosal inocula that were pooled from 5 individual patients 
respectively in each of the groups, BF+bx, BF+NF, BF+T as well as BF-bx. Further, 16S 
rRNA amplicon sequencing analysis of individual patient colonic mucosa identified that 
one of the 5 biofilm-positive tumors was C. difficile positive (19/14000 reads in patient 
3728-T3, Table 2).  This result was validated using C. difficile selective culture followed 
by colony PCR for the tcdB gene. In contrast, we did not identify a C. difficile-positive 
individual patient in BF+NF group based on either 16S rRNA amplicon sequencing results  
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Table 2. C. difficile validation with individual human mucosa from tumors or normal flanking 
regions 
 BF+ Tumor inoculum (#1, 2, 3) * 
 3728-T3 3753-T 3754-T 3756-T 3774-T 
C. difficile 16S rRNA Seq 19/14000 0 0 0 0 
C. difficile culture 











BF+ Tumor inoculum (#1, 2, 3) *  were 3 replicates of human tumor mucosa homogenates combined 
from the same 5 patients. 
 BF+ NF inoculum 
  3726-NF 3753-NF 3754-NF 3756-NF 3774-NF 
C. difficile 16S rRNA Seq 0 0 0 0 0 
C. difficile culture 











 Figure 3.1 C. difficile is detected persistently in human biofilm-positive mucosa and 
subsequently colonized germ-free mice that develop colon tumors. 16S rRNA amplicon 
sequencing was done with DNA extracted from human (h) mucosal inoculum, mouse (m) stools (at 1 
week and 12 weeks) and mouse colonic tissues (at 12 weeks). Human mucosae included biofilm-
negative biopsies (BF-bx), biofilm-positive biopsies (BF+ bx), biofilm-positive normal flanking (BF+ NF), 
and biofilm-positive tumors (BF+ T#1, BF+ T#2, BF+ T#3). Each type of human mucosal homogenate 
inoculum was a mixture combined from 5 patients of each group. T#1, T#2 and T#3 were three replicates 
of tumor homogenates made from the same 5 patients. Relative abundance of Operational Taxonomic 
Units (OTUs) (Y axis) from 16S rRNA amplicon sequencing was calculated as the percentage of 
absolute reads out of 14000 randomly normalized total reads. CIm_2663 (the red star) is the human 
CRC-associated C. difficile isolate cultured from one of the mice (stool at 12 weeks) inoculated with the 
BF+ T#2 human mucosal homogenate. The relative abundance of C. difficile in each type of human 




or microbiology culture. 
 
The mouse stool specimens (provided by our collaborator, Dr. Sarah Tomkovich in the 
laboratory of Dr. Christian Jobin), in which C. difficile was detected by sequencing, were 
used to recover the C. difficile strain. We successfully isolated a C. difficile strain from the 
12-week stool of GF mouse #2663 that was inoculated with human BF+T mucosa and 
named this strain as CRC isolate CIm_2663. This isolate was confirmed as a toxigenic C. 
difficile strain by colony qPCR using the primers/probe for C. difficile 16S rRNA gene 
(TagMan) and primers for tcdA and tcdB (SYBR green). To compare with additional C. 
difficile strains in further experiments, we obtained two ATCC strains, the toxigenic C. 
difficile strain ATCC 9686 and non-toxigenic strain ATCC 700057 (Table 3) and confirmed 
C. difficile 16S rRNA, tcdA and tcdB genes in these strains using qPCR.  
 
 
3.4.2 Establish chronic colonization of C. difficile in SPF ApcMin∆716/+ mouse model. 
To test the colonic tumorigenesis potential of our CRC isolate CIm_2663 in mice, we 
needed to establish a murine model displaying C. difficile chronic colonization for 3 
Table 3. Toxin genes and ribotypes of C. difficile strains used in this study 
Strains tcdA tcdB Ribotype Source 
Non-toxigenic ATCC 700057 - - 038 Human 
Toxigenic ATCC 9689 + + 001 Human 
Toxigenic CIm_2663 (Human 
CRC-associated isolate) + + FP485 
Human CRC-associated strain 
passed through germ-free 
mice 
Toxigenic 630∆erm wild type + + 012 (Refer to strain 630) Derivative of human strain 630 
tcdB⁻ 630∆erm mutant + - 012 (Refer to strain 630) 
Mutant on 630∆erm 
background 
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months. This model differs from the current CDI murine models that exhibit robust acute 
colitis with up to 40%-50% mortality within the first few days after infection (Chen, X. et 
al. 2008; Buonomo et al. 2016; Abt et al. 2015). In the first few pilot studies using 6-8-
week old SPF ApcMin∆716/+ mice (all ApcMin/+ hereafter will be ApcMin∆716/+) in both genders, 
we tested an antibiotic cocktail (Buonomo et al. 2016; Abt et al. 2015) modified from 
reports on current CDI murine models, and initiated a new treatment regime of 
vancomycin (0.050 g/L) and gentamicin (0.035 g/L) in drinking water for 3 days, followed 
by orally inoculation with 103 -106 CFUs of C. difficile spores and gentamicin (0.035 g/L) 
in the drinking water for 12 weeks . The results of fecal culture and species-specific 16S 
rRNA PCR for C. difficile showed that the colonization of C. difficile strains (Table 3) was 
not consistently sustained for 12 weeks (Figure 3.2 A). 
 
The 12-week endpoint colonization ratio was 10% (1/10 mice) for strain ATCC 700057, 
50% (9/18 mice) for strain ATCC 9689 and 27% (3/11 mice) for CRC isolate CIm_2663 
(Figure 3.2B). Subsequently, we improved the colonization persistence by refreshing the 
vancomycin and gentamicin supplemented water every 24-36 hour to maintain antibiotic 
effectiveness for 5-7 days before inoculation while using the same antibiotic formula and 
the number of C. difficile spores for inoculation. Utilizing microbial culture (Figure 3.2C) 
and qPCR (Figure 3.2D), we demonstrated that fecal colonization levels of the three C.  
difficile strains were similar once established and persisted across multiple time points 
during the 12-week study course. The colonization ratio was increased to 50% (4/8 mice) 
for strain ATCC 700057 up to 12 weeks, 100% (8/8 mice) for strain ATCC 9689 up to 12 




Figure 3.2 New antibiotic pretreatment facilitates C. difficile chronic colonization in SPF 
ApcMin∆716/+ mice. A-B. Fecal colonization was detected using qPCR (A) and the ratio of colonized mice 
at 12 weeks in the first few pilot studies. C-E. Fecal colonization was determined by microbial culture 
(C) and qPCR (D) at multiple time points during 12 weeks in two refined experiments. 103 was the 
detection limit of both microbial culture and qPCR. Any value below 103 by qPCR (D) is considered C. 
difficile negative, and this is validated by culture (C). E. The ratio of colonized mice in the two refined 







(5/8 mice) by Week 12 (Figure 2.3E).  Unexpectedly, in contrast to the successful 
colonization of C. difficile strains in SPF ApcMin∆716/+ mice, SPF wild-type mice under the 
same protocol of antibiotic treatment displayed colonization resistance or lost the initial 
colonization after 1 week. Thus, we were unable to establish a chronic colonization model 
of C. difficile in SPF wild-type mice. 
 
3.4.3 Toxigenic C. difficile strains enhance colon tumor formation in SPF 
ApcMin∆716/+ mice. To test whether C. difficile modified tumorigenesis, we inoculated 
ApcMin∆716/+ mice with the CRC isolate CIm_2663 and in parallel also tested the non-
toxigenic strain ATCC 700057 and toxigenic strain ATCC 9689.  We monitored the mouse 
body weight and colitis symptoms like diarrhea or bloody stool. At 12 weeks, colon tumors 
were examined after methylene blue staining as described in Materials and Methods 3.3.6. 
As shown in Figure 3.3A and B, the toxigenic C. difficile strains of CRC isolate CIm_2663 
and ATCC 9689 together significantly enhanced colon tumor formation as compared with 
the sham mice (P = 0.0119) and non-toxigenic strain ATCC 700057 (P = 0.0096) with 
similar tumor sizes (data not shown). When analyzed separately, our human CRC isolate 
CIm_2663 promoted more tumors than sham (P = 0.0198) and non-toxigenic strain ATCC 
700057 (P = 0.0126) (Figure 3.3C). The toxigenic C. difficile strain ATCC 9689 also 
increased tumor incidence in a subgroup of mice, although the statistical difference was 
only significant when compared with non-toxigenic strain ATCC 700057 (P = 0.0419). Of 
note, both toxigenic C. difficile strains predominantly increased tumor formation in the 
distal colon of SPF ApcMin∆716/+ mice. Microadenoma counts examined on H&E-stained 
mouse colon sections showed no difference across the groups at 12 weeks (Figure 3.3D). 
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Figure 3.3 Toxigenic C. difficile strains enhance colon tumor formation in ApcMin∆716/+ mice at 12 
weeks after inoculation. A. Representative pictures of mouse colons that were stained with methylene 
blue; B-C. Mouse colon tumor numbers were shown with toxigenic strains combined (B) or separated 
(C); D. Microadenoma counts by microscopy on H&E-stained mouse colon sections; E. No acute colitis 
signs including significant early body weight loss were observed within the first week after C. difficile 
inoculation in SPF ApcMin∆716/+ mice; F. Later body weight loss, particularly in mice inoculated with 
toxigenic clinical isolate CIm_2663 strain after 8 weeks was shown to correlate with tumor burden. The 
correlation was performed by linear regression analysis. Data represent at least 3 independent mouse 
experiments for each group. The overall P value among multiple groups was calculated using Kruskai-
Wallis test followed by uncorrected Dunn’s test for the comparison of two group. A P value < 0.05 is 


















Overall, the colonization of C. difficile strains under our adjusted antibiotic treatment did 
not lead to any acute death, or rapid onset of symptomatic diarrhea with body weight loss 
(Figure 3.3E). The body weight loss in later time course correlated with tumor counts in 
the mouse colons (Figure 3.3F).  
 
3.4.4 C. difficile colonized SPF ApcMin∆716/+ mice show different morbidity and 
inflammatory features as compared with an acute colitis model using GF wild-type 
mice analyzed at two weeks after inoculation. To better characterize our mouse model 
of C. difficile chronic colonization, we evaluated the disease at the acute phase in SPF 
ApcMin∆716/+ mice and GF wild-type mice. The mouse body weights were monitored 
frequently for the first 2 weeks post-inoculation showed that GF mice inoculated with 
toxigenic C. difficile strains ATCC 9689 or CRC isolate CIm_2663 demonstrated about 20% 
body weight loss (Figure 3.4A), diarrhea, hunched posture and agitation during the first 
2-5 days after the inoculation. Sham GF mice and non-toxigenic C. difficile strain 
inoculated mice did not show any morbidity consistent with acute colitis. The body weights 
for GF sham mice were not monitored to avoid cross contamination from repeatedly 
opening the cages under germ-free condition. The average fecal colonization levels after 
2 weeks in C. difficile inoculated GF mice (Figure 3.4B) were in the range of 106 to 108 
CFUs/g stool. Toxigenic strain ATCC 9689 showed less C. difficile burden in feces relative 
to strain ATCC 700057 and CRC isolate CIm_2663 but displayed more body weight loss 
(Figure 3.4A-B). This suggested that fecal bacterial load alone did not fully explain the 
variations in disease severity. Moreover, we did not observe significant body weight loss 


















Figure 3.4 Morbidity and bacterial burden during/at 2 weeks after C. difficile inoculation in GF wild-
type mice and SPF ApcMin∆716/+ mice. GF wild-type mice were challenged with 104 spores and SPF 
ApcMin∆716/+ mice were challenged with 106 spores. Body weight is presented as percent of the original 
body weight. A-B: Body weight % (A) and fecal colonization (B) in GF wild-type mice inoculated with 
toxigenic C. difficile strains ATCC9689 (n=8) and CRC CIm_2663 (n=8). The body weights of GF sham 
mice (n=10) and mice inoculated with non-toxigenic ATCC700057 strain (n=8) were not documented due 
to lack of disease symptoms, and to maintain GF status of sham mice or avoid contamination for mice 
inoculated with non-toxigenic strain. C-D: Body weight % (C) and fecal colonization (D) in SPF ApcMin∆716/+ 
mice. GF data represent two independent experiments, and SPF data represent one single experiment. 
GF wild-type mice 
 





D). Similar to the colonization outcomes in the 12-week colon tumor experiment (Figure 
3.2), non-toxigenic strain ATCC70057 colonized modestly less well in SPF ApcMin∆716/+ 
mice, while the two toxigenic C. difficile strains showed similar level of bacterial loads at 
106-107 CFUs/g stool at two weeks (Figure 3.4D) when compared with GF mice colonized 
for two weeks with C. difficile (Figure 3.4B). We predicted that the differing morbid 
manifestations between GF wild-type and SPF ApcMin∆716/+ mice during the first 2 weeks 
after infection reflected differential inflammatory responses, suggesting that the host 
mucosal environment impacts disease severity in response to C. difficile infection. In 
addition, we hypothesized that the sub-acute inflammatory characteristics at 2 weeks 
after C. difficile inoculation may persist in the long term and lead to a pro-tumorigenic 
environment in ApcMin∆716/+ mice.  
 
We aimed to profile and compare the colonic tissue-derived cytokine expression by qPCR 
with 0.5 cm middle colon tissues from these two mouse models. As noted, GF wild-type 
mice appeared ill within the first week after infection. Although symptoms appeared 
resolved at 2 weeks, qPCR assay of colonic tissue demonstrated significant upregulation 
of TNF-α, Nos2, IFN-γ, IL-17A, IL-22 and IL-4 upon colonization with toxigenic C. difficile, 
particularly CRC isolate CIm_2663 (Figure 3.5). Increased IL-17A expression was mainly 
driven by toxigenic C. difficile although the non-toxigenic strain also stimulated IL-17A 
expression in some mice. We did not observe a downregulation of IL-25 as previously 
shown by other studies using human colonic tissues from CDI patients and antibiotic-
pretreated SPF mouse models (Buonomo et al. 2016). In contrast, when assayed using 













GF wild-type mice 
 





Figure 3.5 Differential cytokine gene expression in the sub-acute phase at 2 weeks after C. 
difficile inoculation in GF wild-type mice and in SPF ApcMin∆716/+ mice. A. Colonic cytokine gene 
expression phase at 2 weeks after C. difficile inoculation in GF wild-type mice; B. Colonic cytokine 
gene expression at 2 weeks after C. difficile inoculation in SPF ApcMin∆716/+ mice. TaqMan qPCR 
targeting cytokine genes including IL-6 (only included in GF mouse experiment), TNF-α, Nos2, IFN-γ, 
IL-17 (is IL-17A in this figure), IL-22, IL-4, IL-25 were performed using RNA isolated from 0.5 cm colon 
snips at 2 weeks after inoculation. GF data represent two independent experiments, and SPF data 
represent one single experiment. The overall P value among 4 groups was calculated using Kruskai-
Wallis test. The statistical difference between two groups was performed using uncorrected Dunn’s 
test. A P value < 0.05 is considered statistically significant. 
 
SPF ApcMin∆716/+ mice 
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after inoculation did not show differential gene expression between C. difficile-colonized 
mice and sham that, as noted, did not exhibit either body weight loss (Figure 3.4C) or 
colitis signs after inoculation (Figure 3.5).  
 
3.4.5 Spatial localization of C. difficile in mouse colons and tumors. We sought to 
explore the spatial localization and the biofilm-forming capability of C difficile in the colonic 
environment of GF wild-type mice and SPF ApcMin∆716/+ mice at 2 weeks after inoculation. 
To preserve the colonic mucus layer, 3 cm of distal mouse colons were fixed in Carnoy’s 
solution immediately after dissection, followed by paraffin embedding and sectioning as 
described in the Methods. C. difficile species-specific probe and all bacteria universal 
probe for the 16S rRNA gene were applied on distal colon sections for FISH hybridization. 
By confocal microscopy, we visualized C. difficile sparsely localizing in the inner mucus 
layer of the colon while the vast majority populated the luminal space. However, we did  
 not observe a mucus-invasive densely packed bacterial biofilm of C. difficile single 
species in mono-associated GF mice.  
 
To further test whether C. difficile in a microbial community acts as a driver bacterium in 
promoting biofilm formation by recruiting other bacteria to the inner mucus layer, we 
examined C. difficile localization in SPF ApcMin∆716/+ mice at 2 weeks by FISH as described 
above. Similar to GF wild-type mice, we visualized a limited number of C. difficile and 
other bacterial cells in the inner mucus layer but did not identify a bacterial biofilm 
community (Figure 3.7A). The spatial localization of C. difficile strains did not vary 


















Figure 3.6 C. difficile spatial localization in both outer and inner mucus layers in GF wild-type 
mouse colons at 2 weeks after inoculation. The localization of C. difficile strains in GF wild-type 
mouse colons was identified with C. difficile species-specific probe (yellow) for FISH staining, and 
epithelial nucleus were counterstained by DAPI (blue). Mucus on colon sections was visualized with 
PAS staining. Scale bars: 100 μm. Data represent two independent experiments. 
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Figure 3.7 C. difficile spatial localization in SPF ApcMin∆716/+ mouse colons at 2 weeks and 12 
weeks after inoculation. A. C. difficile colonize in both outer and inner mucus layers in SPF ApcMin∆716/+ 
mice at 2 weeks after inoculation. C. difficile localization (green arrows) was identified with the C. difficile 
species-specific probe (yellow) and bacterial universal prole (red) for FISH staining. Epithelial nuclei 
were counterstained by DAPI (blue). B. Tissue-associated C. difficile was quantified by RT-qPCR with 
RNA isolated from tumors or normal colon pieces of SPF ApcMin∆716/+ mice at 12 weeks after inoculation. 
Data represent one single experiment with numbers of mice per group: N = 4 (Sham), N = 2 (Non-
toxigenic ATCC 700057), N = 4 (Toxigenic ATCC 9689) and N = 4 (CIm_2663). Images were obtained 
at 40x magnification. Scale bars: 100 μm.  
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displays a special tumor-associated niche, we performed RT-qPCR with RNA isolated 
from tumor or paired normal colon tissues from SPF ApcMin∆716/+ mice at 12 weeks after 
colonization (Figure 3.7B). The quantification of C. difficile copy numbers in tumors did 
not differ from normal colonic tissues regardless of C. difficile infection status.  
 
Colonic C. difficile has been reported to alter mucus production and composition in CDI 
patients (Engevik et al. 2014). To further understand the impact of C. difficile on the mucus 
barrier, we utilized our GF wild-type mouse model to avoid the influence of the gut 
microbiota. We measured mucus depth on PAS-stained colon sections and quantified To 
further test whether C. difficile in a microbial community acts as a driver bacterium in 
promoting biofilm formation by recruiting other bacteria to the inner mucus layer, we 
examined C. difficile localization in SPF ApcMin∆716/+ mice at 2 weeks by FISH as described  
above. Similar to GF wild-type mice, we visualized a limited number of C. difficile and 
other bacterial cells in the inner mucus layer but did not identify a bacterial biofilm 
community (Figure 3.7A). The spatial localization of C. difficile strains did not vary 
between the non-toxigenic strain and toxigenic strains. To address whether C. difficile 
displays a special tumor-associated niche, we performed RT-qPCR with RNA isolated 
from tumor or paired normal colon tissues from SPF ApcMin∆716/+ mice at 12 weeks after 
colonization (Figure 3.7B). The quantification of C. difficile copy numbers in tumors did 
not differ from normal colonic tissues regardless of C. difficile infection status. 
 
Colonic C. difficile has been reported to alter mucus production and composition in CDI 





Figure 3.8 Toxigenic C. difficile strains induce mucus production in mono-associated GF wild-
type mice. A. PAS staining of the distal 3 cm of colons from GF wild-type mice at 2 weeks after 
inoculation with C. difficile strains relative to sham GF mice. Green brackets demarcate the mucus depth 
(10x magnification, scale bars: 250 μm or 500 μm). B. Comparison of mucus depth among C. difficile 
infection groups. C-E. Muc2 (C), Muc1 (D) gene expression in colonic tissues, and Muc2/Muc1 
expression ratio (E). Data of 8 mice per group from Sham, Toxigenic ATCC 9689 and CIm_2663 groups 
were collected from two independent experiments, and 8 mice inoculated with non-toxigenic strain ATCC 
700057 were from a separate single experiment with additional 2 sham GF mice as control. For mucus 
depth analysis (A and B), numbers of mice per group: N = 8 (Sham), N = 7 (Non-toxigenic ATCC 
700057), N = 7 (Toxigenic ATCC 9689) and  N = 7 (CIm_2663). For gene analysis (C-E), numbers of 
mice per group N = 10 (Sham), N = 7 (Non-toxigenic ATCC 700057), N = 8 (Toxigenic ATCC 9689) and  
N = 8 (CIm_2663). The overall P value among 4 groups was calculated using Kruskai-Wallis test. The 
statistical difference between two groups was performed using uncorrected Dunn’s test. A P value < 
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barrier, we utilized our GF wild-type mouse model to avoid the influence of the gut 
microbiota. We measured mucus depth on PAS-stained colon sections and quantified 
mucus-related gene expression using qPCR at 2 weeks after inoculating C. difficile strains 
into GF wild-type mice. As shown in Figure 3.8A and B, mono-colonization of toxigenic C. 
difficile strains increased mucus depth in C. difficile mono-associated GF mice as 
compared with sham and non-toxigenic C. difficile-infected GF mice. Despite similar 
expression of the mucus-related genes, Muc2 and Muc1, across groups, toxigenic C. 
difficile strains decreased the expression ratio of Muc2/Muc1. These results suggest that 
in response to toxigenic C. difficile strains and C. difficile toxins, the mucus composition 
and secretion by colonic epithelial cells may be modulated. 
 
3.4.6 Phylogenetic analysis of C. difficile strains. To characterize the C. difficile strains 
used in our study, we performed whole-genome sequencing of the human CRC-
associated strain CIm_2663 together with strain ATCC 700057 for which a genome 
sequence has not been published. Referring to publicly available C. difficile whole 
genome sequences, we performed phylogenetic analysis. The result showed that CRC 
CIm_2663 isolate was in a different clade from the toxigenic strain ATCC 9689 or non- 
toxigenic C. difficile strain ATCC 700057 (Figure 3.9). The comparison of tcdA and tcdB 
toxin sequences suggested that tcdB gene regions, harboring 98.1% matched contigs, 
are nearly identical between CRC CIm_2663 isolate and toxigenic strain ATCC 9689, 
whereas tcdA genes differ with only 78.6% matched contigs. At present, we cannot 
specifically test the biological activity of toxin A verses toxin B from C. difficile 
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strains ATCC 9689 and CRC CIm_2663 because of the structural and functional overlap 
between these two toxins. However, we plan to create toxin-specific knock-out strains 









Figure 3.9 Whole genome sequence comparison among strains included in this study. 
Phylogenetic analysis of C. difficile strains CRC CIm_2663 and non-toxigenic ATCC 700057, in 
reference to toxigenic strain ATCC 9689, each highlighted within a red box. 
 
 
Phylogenic Tree of C. difficile Strains 
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3.5 Discussion 
A mouse model of C. difficile infection or colonization should ideally be standardized to 
generate reproducible results and resemble the pathogenesis of human diseases. Our 
chronically colonized SPF ApcMin∆716/+ mice established a new mouse model to examine 
the potential long-term impact on disease pathogenesis in C. difficile carriers. In fact, the 
biologic impact of persistent C. difficile colonization in humans is unknown. Further, our 
data raise the hypothesis that the patient with a congenital or an acquired APC gene 
mutation may face an increased risk of colon tumor development over time if 
asymptomatically colonized with toxigenic C. difficile strains. Determining how commonly 
pro-tumorigenesis is driven by C. difficile strains in human populations requires further 
study. Importantly, C. difficile strains may possess variable disease potential as we see 
our CRC CIm_2663 isolate tends to be more tumorigenic than toxigenic ATCC 9689 in 
SPF ApcMin∆716/+ mice; further, some C. difficile strains, including toxigenic C. difficile 
strains, may not be pro-tumorigenic. Emerging evidence suggests that non-toxigenic 
virulence factors including cell wall proteins, adherence factors and metabolic products 
may influence disease severity in mouse models (Awad et al. 2015). Genome mining and 
experimental work with differing C. difficile strains may even discover new tumorigenic 
virulence determinants. 
 
Antibiotics modify the metabolic activity and the colonization resistance of altered 
microbiota, thereby increasing host susceptibility to C. difficile. In addition to multiple 
antibiotic cocktail regimens, vancomycin priming treatments for C. difficile mouse models 
range from a single administration to daily administration over 5 days with widely variable 
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doses to yield acute C. difficile colitis mouse models. In order to chronically colonize 
ApcMin∆716/+ mice with C. difficile, we adjusted previous antibiotic regimens and utilized 
vancomycin and gentamicin pre-treatment followed by continuous gentamicin in drinking 
water to facilitate sustained and non-lethal C. difficile colonization for 12 weeks in the SPF 
ApcMin∆716/+ mice. Gentamicin has no activity against C. difficile, when given orally, yet 
alters the mouse microbiota sufficiently to be permissive to chronic C. difficile colonization. 
In both pilot studies and later our refined studies, the non-toxigenic C. difficile strain was 
less likely to initiate or sustain persistent colonization under our antibiotic therapy 
approach (Figure 3.2). Interestingly, we have not yet successfully colonized SPF wild-
type mice with C. difficile under the adjusted antibiotic priming. The reason why SPF wild-
type mice were resistant to C. difficile colonization still requires study, however, the 
genetic difference between wild-type and ApcMin∆716/+ mice may impact the gut microbial 
composition, host-microbiota metabolism interactions such as primary bile acid 
availability or influence the protein or other molecule expression of the colon epithelial 
cells, leading to differential susceptibility to C. difficile colonization. Similarly, the more 
consistent and persistent colon colonization by two distinct toxigenic C. difficile strains 
(Figure 3.9) suggests that either the toxins and/or other adherence determinants augment 
C. difficile mucosal colonization potential, an observation of possible importance to 
chronic asymptomatic or symptomatic C. difficile colonization in humans. Further, it may 
be that human with congenital or acquired APC gene mutations may harbor a gut and/or 
mucosal microbiota prone to C. difficile colonization. These data together highlight the 
significance and importance to future research of multi-factor assessment criteria 
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including genetics, microbiota and/or host tissue histology in colonoscopy screening for 
CRC.  
 
GF mice are a valuable experimental tool to investigate host–bacterial interactions in an 
environment devoid of competitive interactions from gut microbiota. In Figure 3.3 and 
Figure 3.4, we show distinct disease course and corresponding differential cytokine gene 
expression at 2 weeks in GF wild-type mice relative to SPF ApcMin∆716/+ mice at the same 
time point. This may be due to the impaired and naïve mucosal and/or systemic immune 
system in GF mice. Importantly,  acute inflammation induced in CDI murine models 
(Buonomo et al. 2016; Abt et al. 2015; Behnsen et al. 2014) has been extensively studied 
and results suggest that IL-17A, IL-22, IL-25 together with neutrophils, eosinophils and 
innate lymphoid cells, ILC3, are important effectors in host defenses and the inflammatory 
pathogenesis. Given C. difficile infection in mice typically induces mucosal inflammation 
at 1 to 4 days, we chose 2 weeks after inoculation when acute inflammation and epithelial 
damage was expected to be resolving based on histology to characterize the 
consequences of persistent colonization that may contribute to colon tumor development. 
Of note, study of a mono-associated mouse model (i.e., inoculation into germ-free mice) 
strongly indicated that C. difficile induces early mucosal inflammation at 2 weeks marked 
by upregulated macrophage, Th17 cell activities and innate lymphoid cell functions 
including upregulated expression of TNF-α and NOS2, IL-17A and IL-22. These results, 
despite not being replicated at this time point in SPF mice, provide potential clues to 
further assess the pro-tumorigenic environment with additional chronic colonization 
experiments that will be described in the next chapter.  
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We did not detect that C. difficile strains assemble biofilms on FISH-stained colon 
sections in SPF ApcMin∆716/+ mice at 2 weeks preceding tumor initiation. Further C. difficile 
16S rRNA qPCR analysis of normal colonic tissues and tumors from SPF ApcMin∆716/+ 
mice at 12 weeks showed that C. difficile does not aggregate specifically in tumor areas, 
consistent with the hypothesis that chronic C. difficile colonization likely precedes onset 
of tumorigenesis. This timeline is consistent with C. difficile being a promoter of colon 
tumor development. Overall, our results encourage us to further consider secreted 
molecules, particularly toxins, to explore the mechanisms by which C. difficile induces 
tumors, a topic that will be discussed in the next chapter. Similarly, we found that even 
GF mice were not permissive to a mono-species C. difficile colon mucosal biofilm but 
rather, our gene expression studies in GF mice suggest that toxigenic C. difficile promotes 
mucus secretion and an alteration of mucus type composition. These results suggest that 
toxigenic, but not non-toxigenic, C. difficile alters barrier function that may contribute to 
chronic colonization and inflammation in the mucosa. Normal colonic mucus is primarily 
composed of secreted MUC2 mucin and cell membrane-associated mucins such as 
MUC1. Mucins are highly glycosylated proteins and altered mucin expression and 
glucosylation have been observed in human colon cancer specimens. Muc2-/- mice 
display aberrant crypts  and adenomas in the small intestine (Velcich et al. 2002). Our 
data suggest that toxigenic C. difficile strains may alter mucin gene expression of 
Muc2/Muc1, however, whether the mucin proteins play a role in colon tumorigenesis in 
ApcMin∆716/+ mice and humans remain to be investigated. It is possible that the mucus 
alteration stimulated by C. difficile is a host defense mechanism. 
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One limitation of these experiments is that the non-toxigenic strain ATCC700057 is not 
an isogenic mutant generated from either toxigenic strains ATCC9689 or CIm_2663. 
Hence, we cannot exclude that other potential C. difficile virulence factors than toxin A 
and B may also contribute to the disease pathogenesis observed from these two strains. 
Further, additional time course experiments and studies of genetically and clinically 
divergent toxigenic and non-toxigenic C. difficile strains would be optimal. 
 
3.6 Conclusion 
Toxigenic C. difficile, particularly our CIm_2663 strain isolated from the colonic mucosa 
microbiota of one CRC patient, induces colon tumorigenesis over 12 weeks in ApcMin∆716/+ 
mice and we propose that C. difficile toxins may be involved in the tumorigenesis 
mechanisms in humans. C. difficile has the capability to establish a mucus-associated 
niche in both GF wild-type and SPF ApcMin∆716/+ mice at 2 weeks. but fails to form mature 
biofilms as either single species or polymicrobial communities, respectively. Further, C. 
difficile induced colon tumor development in SPF ApcMin∆716/+ mice is not accompanied by 
tumor-associated aggregates or biofilms. The specific virulence properties of the CRC 
isolate CIm_2663 and ATCC 9689 including the toxin pathogenicity loci and non-toxin 
virulence factors remain to be identified and characterized with more detailed genomic 
and experimental analysis. 
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Chapter 4  
Persistent C. difficile toxin production induces chronic 
mucosal inflammation and modifies epithelial biology 
that correlates with increased colon tumorigenesis in 
ApcMin∆716/+ mice 
Abstract 
Emerging evidence of certain bacterial species inducing tumorigenesis in animal models 
supports the association between specific pathogenic bacteria and human 
carcinogenesis. The microbial-dependent tumorigenic mechanisms include bacterial 
virulence factors, inflammation and functional and/or genetic alterations in epithelial cells. 
Our results suggest that toxigenic C. difficile-induced colon tumorigenesis in SPF 
ApcMin∆716/+ mice depends on persistent C. difficile toxin production. The persistent toxin 
production during C. difficile chronic colonization facilitates the development of low-grade 
mucosal inflammation that displays predominant infiltration of macrophages in colonic 
mucosa along with differential cytokine expression in tumor environment. We propose 
these features predispose normal epithelial cells to a pro-inflammatory, pro-tumorigenic 




A substantial body of studies illustrates that chronic inflammation predisposes a healthy 
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individual to cancer by re-shaping the tissue microenvironment and epithelial biology over 
time (Gagliani et al. 2014; Arthur et al. 2012). This realization is typically represented by 
the association between chronic inflammatory bowel diseases and the increased risk of 
colorectal cancer (Swidsinski et al. 2009; Grivennikov et al. 2012). Existing data 
demonstrate that the microbiota associated with colon cancer contributes to colon 
tumorigenesis dependent on biologic mechanisms driven by microbial virulence factors 
including inflammation, DNA damage and pro-oncogenic signaling activation (Gao et al. 
2015; Goodman and Gardner 2018; Goodwin et al. 2011; Wu, S. et al. 2009; Rubinstein 
et al. 2013; Arthur et al. 2012). However, the mechanisms by which C. difficile may cause 
colon tumorigenesis in mouse models and humans remains unexplored. 
 
Thus far, outstanding evidence shows that C. difficile toxin A and toxin B are the major 
virulence factors mediating the pathogenesis of C. difficile-induced acute colitis that is 
predominantly characterized by inflammation due to innate immune responses (Awad et 
al. 2015; 1995; Lyras et al. 2009). These toxins are transported into the colonic epithelial 
cells and are known to glucosylate small Rho and ras family GTPases to disrupt the actin 
cytoskeleton and ultimately impair epithelial integrity. Further, toxin A and toxin B induce 
the secretion of inflammatory factors including cytokines, chemokines and reactive 
oxygen mediators that trigger a mucosal inflammatory cascade, such as toxin A and toxin 
B directly activating the epithelial cells, tissue resident macrophages, dendritic cells (DCs) 
to produce epithelial IL-8/CXCL-8, monocyte chemoattractant protein 1 (MCP-1),  
macrophage-derived TNF-α, IL-8/CXCL8, IL-1β, DC-derived IL-1β, IL-6 and IL-23 
(Chandrasekaran and Lacy 2017; Carter et al. 2010; Buonomo and Petri 2015; Solomon 
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2013; Sun and Hirota 2015; Saleh and Petri 2020). These cytokines and chemokines play 
an important role in recruiting neutrophils to the colonic mucosa that is recognized as the 
inflammatory hallmark of CDI-induced acute inflammation (Kelly,Becker, et al. 1994; 
Kelly,Keates, et al. 1994; Linevsky et al. 1997; Kelly and Kyne 2011; Sun and Hirota 2015). 
Furthermore, increasing data suggest that 3 types of Innate lymphoid cells (ILCs) provide 
early protection in various ways during CDI (Geiger et al. 2014; Buonomo and Petri 2015; 
Abt et al. 2015). ILC1-derived IFN-γ, Nos2, and ILC3-derived IL-17A, IL-22 are key 
cytokines predominantly upregulated in response to CDI, and synergistically play 
protective roles from severe CDI disease (Abt et al. 2015; Hasegawa et al. 2014; 2012). 
Interestingly, independent studies found that type 2 cytokines of IL33 (Frisbee et al. 2019) 
and IL25 (Buonomo et al. 2016) are suppressed during human and/or murine CDI. The 
downstream eosinophils contribute to maintaining epithelial integrity likely regulated by 
ILC2 (Frisbee et al. 2019; Buonomo et al. 2016). The adaptive immune responses, 
particularly mucosal Th17 cell functions, have been largely understudied (Saleh and Petri 
2020) as compared with innate immunity in the context of CDI. IgA or IgG antibodies 
against C. difficile toxins provide long-lived protection from recurrent CDI in mouse 
models (Johnston et al. 2014) ; however CD4+ T cells are not required for IgA class 
switching. It remains unclear whether CD4+ T cells or the Th17 subset alone contribute 
to CDI protection or immunopathology in the long term (Ryan et al. 2011; Maseda et al. 
2019).  Overall, on balance, pro-inflammatory responses result in acute colitis marked by 
extensive tissue damage, fluid secretion, bleeding and/or pseudomembranous lesions. 
Moreover, many human CDI cases develop relapse or recurrence potentially triggering 
chronic colitis that is less well-studied in the CDI field. Some studies in mouse models 
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report that colonization with C. difficile causes chronic inflammation lasting up to 1 month 
after the acute CDI symptoms resolve (Buffie et al. 2012). However, the possibility that 
CDI transforms to chronic colon inflammation and the consequence of this putative 
chronic inflammation on epithelial cell biology still needs to be characterized, particularly 
in humans. 
 
In addition to the chronic colon inflammation that C. difficile toxins may induce, the 
potential impact on epithelial cells that are persistently exposed to toxin A and toxin B in 
a chronic fashion has not been well studied. Current studies have only focused on the 
acute effects of toxins on multiple aspects of epithelial cell biology such as disruption of 
cell cytoskeleton and cell-cell tight junctions, induction of  apoptosis and necrosis (Kuehne 
et al. 2010; Chandrasekaran and Lacy 2017). Notably, limited data suggest toxin B, 
instead of toxin A, might be more associated with colon tumorigenesis, although research 
shows controversial results. On one hand, an earlier study found that toxin B activates 
epidermal growth factor receptor (EGFR)-ERK-MAP signaling pathway in human colonic 
epithelial cells (Na et al. 2005), suggesting that toxin B may contribute to promoting 
tumorigenesis. The more recent studies, on the other hand, suggest that toxin B 
competitively binds to Wnt receptor on cell membrane and effectively blocks Wnt/β-
catenin signal activity (Chen, P. et al. 2018; Tao et al. 2016), suggesting an anti-tumor 
activity of toxin B. A newly published study reported that C. difficile toxin B reduced the 
extracellular domain of the cell-cell adherens junctional protein, E-cadherin, at 48  hours 
in infected mouse colons (Mileto et al. 2020), and demonstrated that colonic epithelial 
cells upregulate gene expression of stem cell markers and Wnt signaling targets.  These 
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observations suggest that C. difficile toxin B may activate the Wnt/β-catenin signaling 
pathway as 𝛽𝛽-catenin binds to the intracellular domain of E-cadherin and is released upon 
E-cadherin cleavage. However, more studies are needed to determine whether C. difficile 
toxin B promotes colon tumor formation via altered Wnt/β-catenin signaling. 
 
Additionally, Chumbler and colleagues (Chumbler et al. 2016) demonstrated that at higher 
concentrations (100pM or above), toxin B initiates the assembly of the NADPH oxidase 
(NOX) complex on endosomes leading to aberrant production of endosomal reactive 
oxygen species (ROS) in cultured epithelial cells. It was also suggested that, unlike toxin 
B, toxin A does not enhance ROS production, but causes a glucosylation-dependent 
apoptosis at all concentrations. These data raised the hypothesis that toxin B might 
induce DNA damage by enhancing ROS response. However, another study (Fettucciari 
et al. 2018) demonstrated that toxin B induces early and persistent DNA damage 
independent of ROS pathways in enteric glial cells. Whether the toxin B could provoke a 
robust ROS production in vivo and/or induce DNA damage to possibly contribute to 
tumorigenesis is unclear. 
 
Cytotoxicity assays indicate that Vero and HT29/C1 cells are both susceptible to toxin A 
and toxin B but Vero cells are more sensitive to toxin B and HT29/C1 cells are more 
sensitive to toxin A. However, whether toxin A or toxin B is more essential to disease 
severity in vivo remains to be elucidated. One study (Lyras et al. 2009) showed that a 
tcdA⁺tcdB⁻ strain is completely avirulent in mice whereas in another study, tcdA⁺tcdB⁻  
and tcdA⁻tcdB⁺ strains were similarly virulent (Kuehne et al. 2010). The discrepancy 
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between these two studies may be accounted for by the different methods used to make 
the mutant bacterial strains, which resulted in different cytotoxicity and toxin titers in 
bacterial culture between the mutants. Neither of these two studies measured toxin levels 
or biology in vivo which may be critical to determine the significance of toxin A versus 
toxin B. 
 
Hence, in this study, after assessing the association of toxigenic C. difficile strains with 
chronic inflammation and promotion of colonic tumorigenesis in 12-week colonized 
ApcMin∆716/+ mice (Chapter 3), we sought to further characterize the chronic inflammation, 
cell proliferation and DNA damage associated with longitudinal toxin production in vivo. 
We hypothesized that these changes are important for initiating aberrant crypt foci and 
microadenomas, or to promote later tumor growth in ApcMin∆716/+ mice.  
 
4.3 Materials and Methods   
4.3.1 C. difficile strains and mouse experiment. In this chapter, we analyzed the 
mouse specimens including feces, colonic snips and tumors, and colon sections from 12-
week tumor experiments with SPF ApcMin∆716/+ mice as detailed in Materials and Methods 
3.3.5. C. difficile strains used in those experiments included non-toxigenic strain ATCC 
700057, toxigenic strain ATCC 9689, CRC-associated isolate CIm_2663. In addition, we 
also evaluated tumorigenesis in SPF ApcMin∆716/+ mice inoculated with C. difficile strain 
wild-type 630∆erm and isogenic tcdA⁺tcdB- mutant (see Table 3). Strain tcdA⁺tcdB- 
630∆erm (tcdB knockout strain) was originally constructed on the background of wild-type 
630∆erm by Dr. Dena Lyras in Australia (Lyras et al. 2009). These isogenic strains were 
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generously provided by Dr. Borden Lacy at Vanderbilt University with Dr. Lyras’ kind 
permission. 
 
4.3.2 Cell Culture. Vero and HT29/C1 cells were maintained in DMEM-high glucose 
(Dulbecco's modified Eagle's medium with 4.5g/L glucose, Sigma) supplemented with 10% 
(v/v) FCS (fetal calf serum; Sigma) and penicillin/streptomycin at 37°C in a humidified 
atmosphere of 5% CO2 until confluence.  To pass the cells, the cells were dissociated 
using trypsin-EDTA (0.05%, Thermo Fisher Scientific) and adjusted to the desired cell 
concentration of 2 x 106/ml with complete cell culture medium stated above. We seeded 
96-well plates with 105 Vero cells/well 1-2 days prior to performing the cytotoxicity assay 
or 105 HT29/C1 cells/well 3 days prior to cytotoxicity assay. 
 
4.3.3 Cytotoxicity Assay. 0.02-0.10 g fecal pellet (1 g/ml, e.g., 0.1 g = 0.1 ml) was 
suspended in 9 volumes of sterile PBS (e.g., 0.9 ml PBS to 0.1 g stool) to make a fecal 
homogenate (0.1 g/ml) that is 1:10 dilution of the original feces. Stool homogenates were 
centrifuged at 4,000g, 4°C for 10 min, and the supernatants were diluted in a tenfold 
series using sterile PBS. 10 μl of each dilution was added onto the Vero cells (African 
green monkey kidney cell line, ATCC® CCL-81™) and HT29/C1 cells (human colon 
carcinoma cell line, kindly provided by Dr. Daniel Louvard) at 70%-100% confluence 
cultured in DMEM supplemented with 10% (v/v) FCS and penicillin/streptomycin on 96-
well plates. Cell rounding was scored from each dilution after 24h incubation, and the 
highest dilution with 100% cell rounding that indicated complete cytopathic effects (CPE) 
was recorded as the end-point toxin titer. Toxin titers are expressed as the log10 
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(reciprocal of the highest dilution factor to display 100% cell rounding)/gram stool). All 
assays were carried out in triplicate.  
 
4.3.4 Toxin B ELISA. C. difficile toxin B ELISA was carried out utilizing the Fecal C. 
difficile Toxin B qualitative ELISA Assay Kit (Eagle Biosciences). The stool homogenates 
used in this experiment were previously made for fecal C. difficile colonization 
measurements presented in Chapter 3 and the cytotoxicity assays presented in this 
chapter, to maintain consistency between these assays for comparison and quality control 
purposes. Since this ELISA Kit was designed for human fecal sample analysis, stool 
resuspension was adapted from a 1:5 dilution in the protocol to 1:20 dilution with mouse 
stools of lower weight. We followed the procedure manual for all the other steps. In brief, 
we centrifuged the stool homogenates (1:10 dilution of the original stools) at 10,000 g, 
4°C for 5 min and took 125 μl of supernatant from each sample into a new tube. 25 μl of 
10-fold concentrated fecal sample extraction buffer and 100 μl of distilled water was 
added to make a final volume of 250 μl; the extracted sample was now at a 1:20 dilution 
from the original stool. We pipetted 100μl of controls and extracted mouse stool samples 
into the microwells coated with Toxin B monoclonal antibody, and incubated the microwell 
plate at room temperature, static, for 1 hour. After 5 washes following each incubation, 
100 μl of Toxin B Tracer Antibody and ELISA HRP Substrate were added into each of the 
reactions for toxin B binding and development.  The positive wells turned yellow visually, 
and we stopped the development after 7 min incubation with HRP Substrate. The optical 
absorbance was read at 450 nm using a microplate reader, and toxin B level was 
expressed as Optical Density (OD450).   
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4.3.5 Histopathologic assessment. Mice were necropsied at the end of 12-13 weeks 
after inoculation with C. difficile strains or sham inoculation. We flushed out the colon  
contents with sterile PBS and cut open the colons longitudinally to examine colonic 
tumors as described in Chapter 3. We fixed the colons in 10% neutral buffered formalin 
solution overnight followed by transferring into 0.9% saline supplemented with 0.3% Na3N. 
For histopathology, the colons were Swiss-rolled for paraffin-embedding, sectioning (4 
μm) and hematoxylin and eosin (H&E) staining by Oncology Tissue Services Core Facility 
at the Johns Hopkins University. Histological scoring of inflammation, epithelial damage, 
hyperplasia and crypt organization was performed blindly by S.W. Criteria for histological 
evaluation is detailed in Table 4.   
 
 
4.3.6 Immunohistochemistry (IHC) staining.  Mouse colons were fixed in 10% formalin 
or Carnoy’s solution followed by paraffin-embedding and sectioning as described in the 
Chapter 3. Unstained colon sections were subjected to immunohistochemistry (IHC) 
staining using the following antibodies: anti-Ki-67 (Catalog #NCL-Ki-67p, Leica  
Table 4. Histopathological scoring criteria on mouse colon sections 
Score Inflammatory infiltration Epithelial damage Hyperplasia Crypt Alteration 
0 normal none normal normal 






superficial damage, few 




severe multifocal mucosal 
infiltration with greater 
submucosal involvement 
severe multifocal epithelial 





marked mucosa and 
submucosal infiltration, often 
transmural 


















Biosystems, USA), anti-Phospho-Histone H2AX (Catalog #9718, Cell Signaling, USA), 
anti-CD3 (Catalog #99940, Cell Signaling, USA), anti-Ly-6G (Catalog #87048, Cell 
Signaling, USA), and anti-F4/80 (Catalog #70076, Cell Signaling, USA). The slides were 
dewaxed with xylene and rehydrated through an ethanol serial gradient as described in 
Chapter 3. The rehydrated colon tissue sections were treated with 3% hydrogen peroxide 
to abolish endogenous peroxidase activity and steamed in sodium citrate buffer for 
antigen retrieval. Then, 5% goat serum was applied for 60 min to saturate non-target 
binding sites, followed by incubation with the primary antibodies at 4°C overnight. The 
next day, the slides were washed with TBST buffer (Tris-Buffered Saline 0.1% TWEEN 
®20, Sigma) and incubated with a second antibody (anti-rabbit IgG, Abcam) for 30 min at 
room temperature. The slides were developed with DAB (3,3’-Diaminobenzidine, Abcam) 
Table 5.  Gene List for RT-qPCR analysis 
Cytokine ID of TaqMan™ Gene Expression Assay 
  











Mucin genes  
Muc1 Mm00449604_m1 
Muc2 Mm00458293_g1 






reagent, followed by TBST washes, hematoxylin counterstain, dehydration through an 
ethanol gradient and mounting with coverslips. For the quantification of Ki-67+ or γ-H2AX+ 
cells, 4 or 5 randomly selected areas of normal distal colon demonstrating well-oriented 
crypts from each section were viewed and counted at 20x or 40x magnification using 
Image J. Immune cell infiltration of tumors or normal regions in distal colons were 
quantified using Halo platform (Indica Labs) in the Tumor Microenvironment Lab, Johns 
Hopkins University School of Medicine.  
 
4.3.7 Tissue RNA extraction, cDNA synthesis, and RT-qPCR. Total RNA from 0.5 cm 
normal colon tissue or dissected tumors was extracted using the Direct-ZolTM RNA 
Miniprep kit (Zymo Research) as detailed in Materials and Methods 3.3.7. We used 500ng 
or 1µg of RNA for cDNA reverse transcription using the High-Capacity RNA-to-cDNA Kit 
(Thermo Scientific). The target genes evaluated by the TaqMan™ Gene Expression 
Assay (FAM) are listed in Table 5. The relative mRNA quantities were expressed using a 
standard ∆∆CT method that calculated fold-changes and were normalized to mouse 
GAPDH, a housekeeping gene.  
 
4.3.8 Statistical Analysis 
Statistical analyses were conducted with GraphPad Prism software version 7.0. 
Numerical data without a normal distribution were expressed as means ± SE, and 
differences between two groups were evaluated using Mann-Whitney U test. For multiple 
group comparisons, statistical analysis was performed with nonparametric Kruskal-Wallis 
test followed by uncorrected Dunn’s test for each two-group comparison as we 
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considered each experimental group as independent from others. Differences at P < 0.05 
were considered statistically significant. 
 
4.4 Results  
4.4.1 Persistent C. difficile toxin production correlates with colon tumor counts. In 
Chapter 3, we demonstrated that toxigenic C. difficile strains, particularly the human CRC-
associated C. difficile isolate CIm_2663, enhanced colon tumor formation. To address the 
question whether CRC-associated strain CIm_2663 displays differential virulence features 
to enhance colon tumorigenesis, we first tested if the CRC-associated strain CIm_2663 
produces more toxins. The longitudinal fecal toxin A and toxin B levels were measured at 
multiple time points (week1, week3 or 4, week8 and week12) in C. difficile colonized 
ApcMin∆716/+ mice utilizing the in vitro cell cytotoxicity assays with Vero cells and HT29/C1 
cells. Although each of the two cell lines is susceptible to both toxin A and toxin B, 
previous studies have shown that HT29/C1 cells are more sensitive to toxin A and Vero 
cells are more sensitive to toxin B when the cross activities are diluted out properly. After 
treatment with fecal supernatants, the cell rounding effect on Vero cells modestly 
suggested that CRC-associated strain CIm_2663 may secrete higher titers of toxin A and 
toxin B than the toxigenic ATCC 9689 strain until 4 weeks after colonization (Fig. 4.1A. P 
=0.0044), even when fecal colonization levels are identical between these two strains (Fig 
3.3). The toxin level at week 4 showed a trending correlation with the final tumor counts 
at 12 weeks by linear regression analysis (Fig 4.1C), but there was no correlation between 
1-week (Fig 4.1B) or 8-week (Fig 4.1D) stool toxin levels with tumor counts, suggesting 








Table 6. Qualitative fecal C. difficile toxin B ELISA  
Strains % of Week 1 Toxin B+ (n/N) % of Week 4 Toxin B+ (n/N) 
ATCC 9689 75% (6/8) 50% (4/8) 
CIm_2663 100% (8/8) 75% (6/8) 
Chi-square P value 0.1306 0.3017 
n: numbers of mice that are toxin B positive in stools; N: total mouse numbers per group 
Figure 4.1 Persistent toxin production for 4 weeks correlates with colon tumor incidence. A. Fecal 
supernatants of mice colonized for 4 weeks with the CRC-associated strain CIm_2663 showed higher levels 
of C. difficile toxins in cytotoxicity assay on Vero cells. B. No differential toxin production between toxigenic 
strains was detected on HT29/C1 cells. C-E. Correlation between tumor counts with week 1 (C), week 4 
(D), and week 8 (E) toxin titers on Vero cells. Data represent two independent mouse experiments. Each 
dot in the figures represents one mouse, and overlapped dots are only shown as one dot. Number of mice 
per group: N = 8 for each of Sham, Toxigenic ATCC9689 and CIm_2663 groups, and N = 4 for Non-toxigenic 
ATCC 700057 group. The statistical difference between two groups (A and B) was calculated with Mann-
Whitney nonparametric U test. The correlation (C-E) was performed by linear regression analysis. A P 
value < 0.05 is considered significant.  
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initiation and development in C. difficile colonized SPF ApcMin∆716/+ mice.  
 
HT29/C1 cell cytotoxicity assays were carried out on the same fecal supernatants and   
did not show differential toxin titers between toxigenic ATCC 9689 strain and CRC-
associated strain CIm_2663 at any time point examined (Fig. 4.1B). Notably, we observed 
that 4-week fecal supernatants from mice inoculated with the CRC isolate CIm_2663 
appeared to be less cytotoxic for HT29/C1 cells as compared with Vero cells, while 
toxigenic ATCC strain 9689 shows similar toxin titers between Vero cells and HT29/C1 
cells at each time point. This discrepancy between Vero cells vs HT29/C1 cells, together 
with the previous reports that Vero cell cytotoxic activity is more likely toxin B-mediated, 
suggested that CRC-associated strain CIm_2663 may secrete more toxin B and similar or 
possibly less, toxin A compared to strain ATCC 9689. These results suggest that the toxin 
correlation with tumor counts might be predominantly driven by toxin B.  
 
To further evaluate the association between toxin B and tumor formation, we tested fecal 
toxin B levels by ELISA. All the mice colonized with toxigenic strain ATCC 9689 or CRC-
associated strain CIm_2663 showed positive toxin B titer in 1-week stools, while 6 of 8 
(75%) mice colonized with strain CIm_2663 showed detectable fecal toxin B compared 
with 4 of 8 (50%) mice colonized with ATCC 9689 strain at 4 weeks after colonization 
(Table 6).  
 
Given these data suggesting a potential correlation between toxin B and tumor counts, 





Figure. 4.2 Toxigenic C. difficile strain 630∆erm without persistent toxin B production fails to 
promote tumors in ApcMin∆716/+ mice. A. Tumor counts in mice colonized with A⁺B⁺ wild-type 630∆erm 
and isogenic A⁺B⁻ mutant as compared with sham ApcMin/+ mice; B. fecal colonization assayed by qPCR 
using DNA isolated from Week 1, Week 4 and Week 12 stools; C-D. Toxin titer measured by cytotoxicity 
assays on Vero cells (C) and HT29/C1 cells (D) with fecal supernatant from mice chronically colonized 
with wild-type strain 630∆erm and isogenic A⁺B⁻ mutant. Data represent one single mouse experiment. 
The number of mice per group N = 4 except that one mouse inoculated with wild-type strain 630∆erm 
was excluded from tumor counting (A). This mouse died one day before the harvest at 12 weeks and the 
colon exhibited tissue decay. But, we included the stools from all mice for the analysis of fecal 




tumorigenesis using isogenic C. difficile strains, wild-type toxigenic 630∆erm (tcdA+tcdB+) 
and a toxin-B-negative single mutant (A⁺B−). Here, we inoculated SPF ApcMin∆716/+ mice 
with these isogenic strains and tested tumor development. However, both wild-type  
630∆erm and the A⁺B− mutant strain failed to promote colon tumor formation in 
ApcMin∆716/+ mice as compared with uninfected control mice, although all the infected mice 
were colonized during the 12 weeks after inoculation (Figure 4.2A-B). Fecal toxin B was 
detected only at 1 week after colonization, but not at subsequent time points from the 
mice colonized with wild-type 630∆erm using the Vero cell cytotoxicity assay (Figure 4.2C) 
and HT29/C1 cells (Figure 4.2D). Strain 630∆erm has been recognized as a less virulent 
strain due to less toxin production and lower morbidity in murine models. However, our 
data suggest the level of toxin produced by strain 630∆erm in vivo was similar to the other 
two toxigenic strains we studied at 1 week. However, the lack of persistent toxin-
production after one week suggests that strain 630∆erm is less virulent. In contrast with 
the results of Lyras et al. (Lyras et al. 2009) indicating that that the culture supernatants 
of the A⁺B− mutant strain induced cell-rounding mainly on HT29/C1 cells in vitro 
suggesting a toxin A effect, we found fecal supernatants from mice colonized with the 
A⁺B− mutant strain did not exhibit any cytotoxic activity towards either Vero cells or 
HT29/C1 cells at the lowest dilution (1:100) of the original stools.  
 
4.4.2 Persistent colonization with toxigenic C. difficile strains induces low-grade 
colonic inflammation from SPF ApcMin∆716/+ mice after 12-week colonization. Chronic 
colonic inflammation has long been recognized as one of the CRC risk factors. Despite 
extensive data characterizing the acute inflammatory features at 1-4 days after C. difficile  
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Figure 4.3 C. difficile chronic colonization induces low-grade chronic mucosal inflammation 
scattered in non-tumor colon epithelium that correlates with colon tumor formation in SPF 
ApcMin∆716/+ mice at 12 weeks after inoculation. A. Mouse colon histopathology image obtained at 
20x magnification, scale bar: 100 μm); B. Inflammation score; C. Correlation between inflammation 
score and tumor counts was performed by linear regression analysis; D. Epithelial damage score; F. 
Altered crypt score. Data represent at least three independent mouse experiments. The overall P value 
among 4 groups was calculated using Kruskai-Wallis test, and the statistical difference between two 













infection in murine models, it remains uncertain whether persistent asymptomatic C. 
difficile colonization invokes chronic inflammation that may contribute to long-term 
pathogenesis of chronic conditions. To evaluate C. difficile-induced mucosal inflammation 
and its correlation with colon tumorigenesis in our vancomycin and gentamicin primed 
SPF ApcMin∆716/+ mouse model, we examined the colonic histopathology on H&E-stained 
colon sections (Figure 4.3A) at 12 weeks after C. difficile colonization. The overall 
histological evaluation suggested that the toxigenic C. difficile strains induced low-grade 
and patchy inflammation in colonic mucosa characterized by immune cell infiltration (see 
criteria in Table 5). The inflammatory scores show that toxigenic C. difficile strains, as 
compared with sham and non-toxigenic strain ATCC 700057, induced more infiltrating 
immune cells in the lamina propria (Figure 4.3B), and this inflammation correlated with 
colon tumor counts by regression analysis (Figure 4.3C). We did not find differential 
chronic epithelial damage (Figure 4.3D) or altered crypt morphology (Figure 4.3E) across 
the groups. These results suggest that immune mechanisms are involved in C. difficile-
induced colon tumorigenesis. 
 
To better understand the nature of the chronic mucosal inflammation associated with 
chronic C. difficile colonization, we analyzed cytokine expression by qPCR using colonic 
tissue snips from SPF ApcMin∆716/+ mice inoculated with non-toxigenic or toxigenic strains. 
Generally, the cytokine gene expression identified in the normal colonic tissues was 
identical across the groups; however, tumors tended to show upregulation of some pro-
inflammatory and regulatory cytokines. Pro-oncogenic cytokines such as IL-17A and 
tumor necrosis factor 𝛼𝛼 (TNF-α) were highly upregulated in ApcMin∆716/+ mouse colon  
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Figure 4.4 Colonic cytokine profile in SPF ApcMin∆716/+ mice at 12 weeks after inoculation. 
Inflammatory cytokine gene expression was evaluated using TaqMan gene expression assays with non-
tumor normal tissues and tumors at 12 weeks after inoculation. mRNA quantities were calculated as 
∆∆CT for fold-changes and normalized to mouse GAPDH. Error bars represent the mean ± SEM on a 
linear scale and geometric mean ± SD on a log scale. Data represent two independent mouse 
experiments, and each dot represents one single mouse. Statistical significance between groups was 
analyzed by the Mann–Whitney nonparametric U test. A P < 0.05 was considered statistically significant. 
The statistic difference between normal region and tumor tissue in Non-toxigenic ATCC 700057 group 
was not assessed because only 1 tumor was available. For IL-4, the overall statistics across all 
subgroups was performed using Kruskai-Wallis test. 
N: Normal colon tissue (no visible tumors); T: Tumors in mouse colons  
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tumors regardless of infection status (Fig 4.4). In contrast, IFN-γ, an anti-tumorigenic 
cytokine, was increased only in sham tumors but not in the tumors associated with C. 
difficile colonization, suggesting that C. difficile may suppress the putative IFN-γ anti-
tumor immune responses. Transforming growth factor β (TGF-β), as an anti- inflammatory  
cytokine, was also increased in all the tumors across the infected groups and sham mice, 
suggesting the regulatory immune responses are at play in the tumor environment in SPF 
ApcMin∆716/+ mice. IL-25, also known as IL-17E, is a cytokine that mainly promotes Th2 
immune response and activates ILC2 cells. Previous studies have reported that intestinal  
IL-25 is suppressed during C. difficile infection in both humans and mouse models 
contributing to the pathogenesis of active colitis (Buonomo et al. 2016). Interestingly, IL-
25 decelerates tumor cell growth in vitro and in xenograft mouse models (Benatar et al. 
2010). A recent study reported that the blockade of IL-25 with neutralizing antibody 
increased tumor burden in a colitis-associated cancer murine model, 
Azoxymethane/Dextran Sodium Sulfate (AOM/DSS) model (Thelen et al. 2016). Here, we 
present that intestinal IL-25 expression was also suppressed in tumors from ApcMin∆716/+ 
mice that were chronically colonized by toxigenic C. difficile strains. Further studies are 
needed to investigate whether IL-25 suppression contributes to C. difficile-associated 
tumor development, and to determine the cellular sources of IL-25 production. 
 
We further characterized the immune cell populations infiltrating in tumors (Figure 4.5) 
and in non-tumor normal regions (Figure 4.6) from sham and C. difficile-colonized 
ApcMin∆716/+ mice at 12 weeks. T cells, neutrophils and macrophages on mouse colon 
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Figure 4.5 Immune cell infiltration in colon tumors from ApcMin∆716/+ mice at 12 weeks after 
inoculation. IHC staining of immune cells in colon tumors using antibodies against cell surface 
markers CD3, Ly-6G and F4/80. A. A tumor from one of the sham mice. B. A tumor from one of the 
CRC isolate CIm_2663 inoculated mice. C-E. Quantification of immune cells, CD3+ (C), Ly6G+ (D), or 
F4/80+ (E) cells, infiltrating in lamina propria was performed using immune cell module on Halo 
platform (Indica Labs). Immune cell counts were normalized by tumor area included in the analysis.  
Upper panel images were obtained at 10x magnification, scale bars: 250 μm. Insets were obtained at 
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Figure 4.6 Immune cell infiltration in non-tumor normal colon regions from ApcMin∆716/+ mice at 
12 weeks after inoculation. IHC staining of immune cells in colon tumors using antibodies against cell 
surface markers CD3, Ly6G and F4/80. A. A representative normal distal colon from one sham mouse; 
B. A representative normal distal colon from one mouse inoculated with non-toxigenic strain ATCC 
700057; C. A representative normal distal colon from one mouse inoculated with CRC isolate CIm_2663. 
D-F. Quantification of CD3+ (D), Ly6G+ (E), or F4/80+ (F) cells in lamina propria was performed using 
immune cell module on Halo platform (Indica Labs). CD3+ or Ly6G+ cells were counted manually with 
the slide viewed on Halo. Immune cell counts were normalized by colon length included in the analysis. 
G. Correlation between F4/80+ macrophages and tumor counts. Images were obtained at 40x 
magnification, scale bars: 50 μm. 
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Figure 4.7 CRC Patient 3728 tumor mucosa that contains toxigenic C. difficile CIm_2663 induces 
a rapid recruitment of neutrophils but macrophages infiltrate the lamina propria over time in GF 
ApcMin∆716/+ mice. A. IHC staining for neutrophils or macrophages was performed using anti-Ly6G or 
anti-F4/80 antibodies respectively on the 3 cm distal colons from sham mice and mice inoculated with 
Patient 3728 tumor mucosa at Day 4 or Day 28 after inoculation. C-D. Quantification of Ly-6G+ (C) or 
F4/80+ (D) cells in lamina propria was performed using immune cell module on Halo platform (Indica 
Labs) and normalized by crypt numbers included in the analysis. Left panel images were obtained at 










markers CD3, Ly-6G and F4/80, respectively. The tumors from sham (Figure 4.5A) or 
CRC isolate CIm_2663 colonized mice (Figure 4.5B) displayed similar F4/80 positive 
macrophages as the major infiltrating immune cell population along with mild to modest 
CD3 positive T cells and neutrophils at 12 weeks after inoculation. To characterize chronic 
inflammation induced by C. difficile, we examined infiltrating immune cells in non-tumor 
normal colon regions also at 12 weeks after inoculation. Similar to tumors, macrophages 
present as the major cell type infiltrating into the lamina propria across the groups (Figure 
4.6), whereas some patchy T cell infiltration and rare neutrophils were found by IHC 
straining. Macrophage infiltration does not appear to depend on C. difficile infection but 
is trending to correlate with tumor burden. Together, our results show that the chronic 
colonization with CRC isolate CIm_2663 may only provoke low-grade inflammation that is 
unlikely to distinguish from sham mice or mice inoculated with non-toxigenic strain ATCC 
700057 at 12 weeks after inoculation. Macrophages in the colon mucosa of ApcMin∆716/+ 
mice (Fig 4.6) are predominant cell population along with the tumorigenic process. 
 
To further evaluate whether the macrophage recruitment marks C. difficile-induced 
chronic inflammation, we assessed the transition of macrophage infiltration in the colon 
mucosa from day 4 to day 28 in GF ApcMin∆716/+ mice colonized with human CRC tumor 
mucosal homogenate from Patient 3728. Ly-6G+ neutrophils showed a rapid and 
temporary response to the homogenate inoculum that includes C. difficile. The F4/80 IHC 
staining on colon sections demonstrated that macrophages are increasingly recruited into 
the colon lamina propria at day 28 relative to day 4 after inoculation with Patient 3728 















Figure 4.8 Low-grade chronic inflammation in non-tumor colon tissues is accompanied by 
epithelial cell proliferation at 2 weeks and 12 weeks after colonization. A. Hyperplasia score 
evaluated based on crypt length on H&E-stained colon sections at 12 weeks after inoculation; B. 
Hyperplasia score at 12 weeks correlates with tumor counts. Data in A and B represent at least three 
independent mouse experiments, and each dot represents one single mouse; C. IHC-stained epithelial 
cells using anti-Ki-67 antibody on non-tumor normal regions of distal colon sections at 2 weeks after C. 
difficile inoculation; D. Quantification of Ki-67+ cells along the colonic crypt axis from base to top. 4 or 5 
locations were randomly selected for quantification of Ki-67+ cells. Each half of 2 well-oriented crypts on 
one photograph was selected for total cell and Ki-67+ cell counting. Results were quantified from the 
crypt bottom (0-5 cells from the crypt bottom) to the crypt top (>10 cells from the crypt bottom). The 
overall P value among 4 groups was calculated using Kruskai-Wallis test, and the statistical difference 
between two groups was performed using uncorrected Dunn’s test. A P value < 0.05 is considered 
significant. 
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genome sequencing data showed that C. difficile isolate #3728-3 from the tumor mucosal 
sample of Patient 3728 is genetically identical to our isolate CIm_2663 isolate from GF 
mice inoculated with same patient sample (Figure 3.9). CD3+ T cells were rarely detected 
by IHC staining (data not shown). 
 
4.4.3 Promotion of epithelial proliferation may be pro-tumorigenic when ApcMin∆716/+ 
mice are colonized chronically with toxigenic C. difficile strains. We aimed to 
address whether epithelial cell biology was changed when ApcMin∆716/+ mice were 
colonized mouse colon tumor counts (Figure 4.8B). In contrast, mice inoculated with non- 
toxigenic C. difficile strain showed similar histopathology to sham mice. To evaluate 
whether low-grade mucosal inflammation induced by toxigenic C. difficile strains is 
accompanied by epithelial cell proliferation, we examined cell proliferation by IHC using 
an antibody against the nuclear protein Ki-67 (Figure 4.8C) at 2 weeks after C. difficile 
colonization in SPF ApcMin∆716/+ mice. Similar to the colon epithelial hyperplasia at 12 
weeks, Ki-67 positive cells were significantly increased in mice colonized with toxigenic 
C. difficile strains at 2 weeks after colonization (Figure 4.8C). This result suggests that 
toxigenic C. difficile strains (and hence their secreted toxins) associate with both early 
and long-lasting colon epithelial cell proliferation, thereby possibly facilitating tumor 
development.  
 
To determine whether pro-tumorigenic signaling pathways in colonic epithelial cells are 
altered in the context of toxigenic C. difficile and chronic inflammation, we quantified 
Wnt/β-catenin regulated genes including c-Myc, Lgr5, Axin2, CCND1 and CD44 (Table 5) 
 93 
  
Figure 4.9 The expression of Wnt/β-catenin regulated genes in normal colonic tissues and 
tumors in SPF ApcMin∆716/+ mice at 12 weeks after inoculation. Wnt/β-catenin downstream genes 
that were examined in this study include c-Myc, Lgr5, Axin2, CCND1 and CD44 in normal colons relative 
to tumors using RT-qPCR assay. Data represent two independent mouse experiments, and each dot 
represents one single mouse. Statistical significance between groups was analyzed by the Mann–
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Figure 4.10 DNA damage assessment by γ-H2AX staining in SPF ApcMin/+ mice at 2 weeks and 12 
weeks after inoculation. The epithelial cells with more than four γ-H2AX+ nuclear foci (r-foci) were 
counted as rH2AX+ cells. A. IHC-stained mouse distal colon for γ-H2AX at 2 weeks after inoculation with 
CIm_2663 as compared with sham mice. Data at 2 weeks were not quantified as very few γ-H2AX+ 
cells/condition were identified. Images present one mouse experiment with 4 mice/group; B. γ-H2AX 
staining on colon sections at 12 weeks and treatment conditions include Sham, Non-toxigenic ATCC 
700057 and CIm_2663. Black arrow heads identify γ-H2AX+ epithelial cells. C. γ-H2AX+ epithelial 
cells/crypt were quantified at 12 weeks. Images present two separate mouse experiments with 4-5 
mice/group. Images were obtained at 40x magnification, scale bars: 50 μm.   
C 
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in normal colon tissues relative to tumors using RT-qPCR assays. All these genes were 
upregulated in ApcMin∆716/+ mouse colon tumors suggesting that Wnt signaling in tumors 
is activated independent of the status of C. difficile infection and toxin production (Figure 
4.9), a result consistent with use of the ApcMin∆716/+ mouse model. However, the increased 
expression of these genes was not detected in non-tumor colon tissues, indicating that 
Wnt/β-catenin signaling in normal colon was not altered by toxigenic C. difficile 
colonization, at least, at the time point examined.  
 
Next, we evaluated DNA damage using an IHC antibody against phosphorylated histone 
H2AX (γ-H2AX is the most abundant phosphoepitope and used as the marker of DNA 
damage) on mouse colon sections at multiple time points. The results showed that 
toxigenic C. difficile colonization did not augment DNA damage in normal colon tissues 
either at 2 weeks or at 12 weeks after inoculation, although we observed γ-H2AX+ cells 
more frequently at 12 weeks than 2 weeks. 
 
4.5 Discussion 
As described to date, CDI is a toxin-mediated colonic disease. However, humans infected 
by the same epidemic strain often show a wide range of clinical outcomes from 
asymptomatic colonization, mild diarrhea through more severe and even life-threatening 
disease such as pseudomembranous colitis. We herein hypothesize that toxin production 
by C. difficile in vivo may be regulated differentially between individuals leading to variable 
host immune responses and disease courses. For the first time to our knowledge, we 
evaluated longitudinal in vivo toxin production in a mouse model. Although C. difficile toxin 
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induces acute colitis, very little is known about the time course and/or role of persistent 
C. difficile toxin production in fostering chronic colon disease. Our results suggest that 
persistent toxin production for 4 weeks correlated with the final tumor counts at 12 weeks. 
This result is further supported by the fact that toxigenic C. difficile strain 630∆erm that 
produced toxins only for one week in vivo failed to enhance tumorigenesis (Figure 4.2). 
Although this correlation is insufficient to firmly identify a role for the C. difficile toxins in 
tumorigenesis, our results highlight the merit of measuring toxin production longitudinally 
in chronic disease evaluation. The combination of toxin assessment over time in humans 
who are asymptomatic C. difficile carriers and corresponding colonic immune responses 
may help to inform the pathogenesis of chronic C. difficile colonization and its potential 
impact on chronic colon disease(s). 
 
In order to determine the role of toxin B in colon tumor formation, we utilized wild-type 
630∆erm and isogenic A⁺B− mutant C. difficile strains generated by Dr. Dena Lyras (Lyras 
et al. 2009) in our mouse model. In contrast to previously published studies, data from 
our mouse model drew our attention to some unique aspects. First, in the pilot study with 
a limited number of mice (Figure 4.2A), wild-.type 630∆erm did not enhance tumor 
incidence after 12 weeks of colonization in ApcMin∆716/+ mice, indicating that the C. difficile 
pro-tumorigenic capability may be a strain-specific property. Second, previous studies 
reported that 630∆erm is a less virulent strain due to the lower toxin production in vitro. 
However, we found similar levels of cytotoxicity with one-week fecal samples in 
ApcMin∆716/+ mice colonized with 630∆erm and ApcMin∆716/+ mice colonized with two other 
toxigenic C. difficile strains (compare Fig 4.1 and 4.2). The most obvious difference 
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between the pro-tumorigenic C. difficile strains (CIm_2663 and ATCC 9689) and 630∆erm 
is that 630∆erm strain lacked the capability to sustain toxin production beyond one week, 
suggesting that persistent toxin-production may be critical to the ability of a C. difficile 
strain to induce colon tumorigenesis and possibly other colon chronic diseases. 
Alternatively, there may be additional differences such as mucosal adhesion or toxin 
delivery mechanisms that contribute to the inability of the 630∆erm C. difficile strain to 
induce colon tumorigenesis. Although in the original Lyras’ study (Lyras et al. 2009), the 
630∆erm isogenic A⁺B− mutant strain was mostly avirulent in a hamster model, they only 
tested the presence of toxin A and the absence of toxin B using an in vitro cytotoxicity 
assay with C. difficile culture broth. Toxin A and toxin B production in vivo along with 
disease status was not assayed. C. difficile toxin production has been suggested to be a 
process highly regulated by the local environment, i.e., the colon. Our work emphasizes 
the importance of assessing in vivo toxin production over time in defining the 
pathogenesis of C. difficile infection in animal models. Consistent with other studies, Vero 
cells and HT29/C1 cells are both susceptible to toxin A and toxin B. Discerning the 
cytopathic effect of toxin B from toxin A in mouse stools using these two cell lines is 
insecure, however our results (Figure 4.1A-B) tentatively represent differential cytotoxic 
effects of toxin A or toxin B. Isogenic mutants of A⁺B−, A−B⁺ and A−B− strains are required 
to definitively answer these questions. 
 
We established a mouse model supporting C. difficile persistent colonization and 
demonstrated the unique features of chronic mucosal inflammation by histologic 
evaluation, colonic cytokine expression and immune cell infiltration after 12 weeks of 
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colonization. We observed that mice colonized with toxigenic C. difficile strains tend to 
show a correlation between higher scores of inflammation and hyperplasia and 
tumorigenesis in SPF ApcMin∆716/+ mice. Although toxigenic C. difficile strains induce 
significant upregulation of colonic cytokine expression, particularly TNF-α, NOS-2, IL-17A, 
in GF wild-type mice after 2-week colonization, these cytokines in infected SPF 
ApcMin∆716/+ mice remain similar to sham at 2 weeks or 12 weeks in non-tumor normal 
colon tissues. Our findings of an association between inflammation (Figure 4.3) and 
hyperplasia (Figure 4.8) with tumor multiplicity suggest that low-grade mucosal 
inflammation is associated with tumorigenesis in our antibiotic-treated SPF ApcMin∆716/+ 
mouse model. However, additional studies are needed to define the tumor-promoting 
cells and/or molecules such as cytokines involved in C. difficile-induced tumorigenesis.  
 
Our findings present a differential inflammation-dependent mechanism involved in C. 
difficile-induced tumorigenesis as compared with enterotoxigenic Bacteroides fragilis 
(ETBF)-induced tumors in SPF ApcMin∆716/+ mice where IL-17A-associated inflammation 
is a hallmark of the tumorigenic microenvironment (Wu, S. et al. 2009; Chung et al. 2018; 
Thiele Orberg et al. 2017; Hurtado et al. 2018). Our preliminary investigations to 
characterize C. difficile-induced low-grade chronic inflammation in distal colons by 
immunohistochemistry suggested that predominant F4/80+ macrophages infiltrating into 
lamina propria and tumors may contribute to tumorigenic environment induced by 
toxigenic C. difficile strains. Neutrophils appear to be a fast but transient responder to C. 
difficile infection. As less abundant on colon sections by IHC, CD3+ T cells from lamina 
propria may need to be enriched and profiled in future studies by flow cytometry to testify 
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the role of IL-17A-associated inflammation in C. difficile-induced tumorigenesis. To 
characterize early inflammation after C. difficile colonization in ApcMin∆716/+ mice will inform 
the inflammatory signatures better than the low-grade chronic inflammation. More 
importantly, acute inflammation likely diminishes epithelial barrier function (increasing 
colon permeability) that is considered a key feature of early colon tumorigenesis and likely 
persists as the chronic inflammatory response develops (Grivennikov et al. 2012). 
 
Additionally, histologically scored epithelial hyperplasia at 12 weeks and quantified Ki-67-
marked cell proliferation at 2 weeks are consistent with the hypothesis that the low-grade 
chronic inflammation may foster a persistent proliferative, pro-tumorigenic mucosal 
environment. This is consistent with previous work by our laboratory that shows that 
human colonic biofilms predispose normal colon tissue to a pro-carcinogenic status with 
epithelial hyperproliferation (Dejea et al. 2014). We also tested whether the pro-
tumorigenic status of the colonic epithelial cells involves Wnt/β-catenin signaling 
activation or DNA damage. Our results showed that Wnt/β-catenin target gene expression 
and colon epithelial cell DNA damage are enhanced in tumors but not detected in normal 
colon tissues of both sham and toxigenic C. difficile chronically colonized SPF ApcMin∆716/+ 
mice at 12 weeks. Thus, differential Wnt signaling and/or colon epithelial cell signaling 
was not seen with C. difficile colonization at the time points examined. Future work on the 
time course and mechanisms of colon epithelial cell signaling, DNA damage and immune 




Our results show that persistent production of C. difficile toxins in the genetically 
susceptible (i.e., ApcMin∆716/+) SPF mouse colons is associated with excess colon tumor 
development. A critical question is to precisely determine the contributions of C. difficile 
toxin A and/or toxin B in colon tumor promotion by C. difficile. To accomplish this goal, 
the isogenic mutants of A⁺B−, A−B⁺ and A−B− strains on the genetic background of CRC 
CIm_2663 will need to be constructed and tested in our chronic colonization mouse model. 
Our results also suggest that the unique mechanism(s) by which, at least, certain 
toxigenic C. difficile strains promote tumorigenesis likely involves elements of acute then 
chronic inflammation. Macrophages are predominant cell population in the colon mucosa 
of ApcMin∆716/+ mice accumulating over time along with the tumorigenic process. In future 
studies, we propose that detailed immunologic profiling and RNA-Seq, particularly of the 
myeloid and T cell populations, may yield insights into a pro-tumorigenic colon mucosal 
environment that fosters persistent colon epithelial hyperplasia and dysplasia. 
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Chapter 5  
Summary 
5.1 General discussion. Increasing studies in recent years highlight the important 
feature that polymicrobial biofilms are associated with or contribute to the pro-tumorigenic 
microenvironment in which human CRC arises. A few studies (Wong et al. 2017; Li et al. 
2019; Tomkovich et al. 2019) have revealed that mucosal or fecal microbiota from CRC 
patients induce  tumor formation in murine models. Thus, the identification of pro-
carcinogenic driver bacterial species or microbial consortia is an urgent and necessary 
question in this field. The mechanisms by which biofilms promote tumor development can 
range from microbial virulence to host immune activation and altered epithelial biology. 
16S rRNA amplicon profiling in the studies presented in this thesis identified C. difficile as 
a consistent species present in human BF+ colonic mucosa that subsequently colonized 
mouse mucosa and feces in mice inoculated with human BF+ mucosal homogenates. 
However, whether and how C. difficile may contribute to CRC remains unknown. We 
aimed to test the tumorigenic potential and the capability to assemble biofilms of C. 
difficile using the genetic murine model of CRC, ApcMin/+ mice, known to be susceptible 
to intestinal tumor formation. We characterized the unique features associated with C. 
difficile-induced tumors and elucidated some of the mechanisms by which C. difficile may 
mediate colon tumorigenesis. Our results will inform future human epidemiologic studies 
to identify the relationship between C. difficile carriage and the risk of CRC development.  
 
In this study, we established a mouse model to foster C. difficile chronic colonization and 
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inoculation of SPF ApcMin∆716/+ mice with toxigenic C. difficile strains, particularly our CRC-
associated isolate, yielded a colon tumorigenic phenotype with colon tumor multiplicity. 
After strain inoculation and mouse colonization, C. difficile strains (non-toxigenic ATCC 
700057, toxigenic ATCC 9689 and toxigenic CIm_2663), regardless of carrying toxin A 
and toxin B, displayed largely similar levels of fecal bacterial burden at each of the time 
points evaluated during 12-week experiments. However toxigenic strains (tcdA+ tcdB+) 
significantly enhanced tumor incidence as compared with the non-toxigenic strain (tcdA- 
tcdB-). These findings suggested that C. difficile promotes colon tumorigenesis that is 
dependent on a toxin A and toxin B production. One limitation of these experiments is the 
non-toxigenic strain ATCC 700057 is not an isogenic mutant generated from either of the 
toxigenic strains (ATCC 9689 and CIm_2663). Hence, we cannot exclude the tumorigenic 
potential of other C. difficile virulence factors that differ genetically in these strains. A 
thorough genomic comparison of these three strains may provide important clues to the 
identification of new virulence factors and development of specific toxin-knockout strains 
from C. difficile strain Clm_2663 will further test the specific importance of Toxin A and/or 
Toxin B in C. difficile-induced colon tumorigenesis (in progress).  
 
C. difficile 16S rRNA-specific qPCR analysis of normal colonic tissues and tumors found 
that C. difficile did not selectively accumulate in tumor areas of ApcMin∆716/+ mice. FISH 
analysis with a C. difficile 16S rRNA specific probe demonstrated the vast majority of C. 
difficile cells localized in the colon lumen with sparse invasion into the inner mucus layer 
in the colons of both GF wild-type mice and SPF ApcMin∆716/+ mice. Our results clearly 
showed that C. difficile strains, including the isolate from CRC-associated biofilms, did 
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not re-assemble mucus-invasive biofilms that adhere to colonic epithelium after 2 weeks 
of colonization. These findings could suggest that C. difficile serves as a driver bacterium 
in colon tumorigenesis and/or works with a bacterial consortium to modulate epithelial 
biology. These possibilities encourage us to further consider the role of secreted 
molecules, particularly toxins, as well as putative C. difficile-associated quorum-sensing 
mechanisms as possibilities for direct (e.g., toxin) and/or indirect (e.g., inflammation) pro-
tumorigenic C. difficile-epithelial cell interactions. 
 
Given the importance of C. difficile toxins in colitis pathogenesis (Chandrasekaran and 
Lacy 2017; Viswanathan et al. 2010; Kuehne et al. 2014) and controversial effects toxin 
B on tumorigenic signaling (Na et al. 2005; Tao et al. 2016; Chen, P. et al. 2018), C. 
difficile toxins, particularly toxin B, are likely to modulate the tumor microenvironment. We 
investigated whether toxin A and toxin B production may, at least partly, contribute to the 
tumor multiplicity in vivo. To quantify toxin A and toxin B production, we performed 
cytotoxicity assays on Vero cells and detected higher cytotoxicity titers with the fecal 
samples from the mice colonized with the CRC-associated isolate. This strain appeared 
to induce more tumors in ApcMin∆716/+ mice. In contrast, toxin A and toxin B production was 
not detected in the feces of the mice colonized with a different toxigenic C. difficile strain, 
wild-type 630∆erm (tcdA+ tcdB+), at the 4-week time point. This strain also did not promote 
colon tumor formation in ApcMin∆716/+ mice. Together these data suggested an important 
correlation between the persistent production of C. difficile toxins and colon tumorigenesis 
in our CRC murine model. However, it remains unclear how toxin A and toxin B production 
is regulated in vivo and how this persistent toxin stress impacts colon epithelial cell and 
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mucosal immune cell functions to contribute to colon tumor initiation and/or subsequent 
tumor progression. Nevertheless, our results highlight the need to investigate longitudinal 
C. difficile toxin production in human patients with CDI or asymptomatic carriers to 
determine if a subset of CDI patients develop chronic colonization with persistent low level 
mucosal inflammation putatively conducive to the development of CRC over time. This 
may be particularly relevant in patients with IBD where both C. difficile persistence in the 
colon and an increased risk for colitis-associated CRC is known (D’Aoust et al. 2017; 
Baker et al. 2019).  
  
To demonstrate the features of chronic mucosal inflammation caused by 12-week C. 
difficile colonization, we evaluated mouse colon histology and mucosal immune cell 
infiltration using immunohistochemistry. The inflammation score and hyperplasia score 
were increased by toxigenic C. difficile strains and correlated with tumorigenesis in SPF 
ApcMin∆716/+ mice. Of interest, the toxigenic C. difficile strains induced significant colonic 
cytokine expression, particularly TNF-α, NOS-2, IL-17A and IL-22, in the colon epithelium 
of GF wild-type mice after 2-week colonization. However, we did not detect differential 
up-regulation of these cytokines in infected SPF ApcMin∆716/+ mice at 2 weeks or 12 weeks, 
suggesting a low-grade, subclinical mucosal inflammation may contribute to 
tumorigenesis in our antibiotic-treated SPF mouse model. These findings present a 
different mechanism when compared to ETBF-induced tumorigenesis in SPF ApcMin∆716/+ 
mice in which IL-17A-associated inflammation is a hallmark of the tumorigenic 
microenvironment (Wu, S. et al. 2009; Chung et al. 2018). Our preliminary investigations 
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immunohistochemistry suggested that predominant F4/80+ macrophage and possible CD3+ 
T cells infiltrating into lamina propria may contribute to tumor development induced by 
toxigenic C. difficile strains. This low-grade chronic inflammation is accompanied by 
histologically-scored epithelial hyperplasia at 12 weeks and quantified Ki-67-marked cell 
proliferation at 2 weeks, suggesting a pro-tumorigenic, proliferative mucosal state. However, 
Wnt/β-catenin target gene expression and epithelial DNA damage are enhanced in 
tumors but not detected in normal colon tissues at 12 weeks and/or 2 weeks after C. 
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difficile colonization in SPF ApcMin∆716/+ mice, hereby suggesting pro-tumorigenic 
signaling in epithelial cells is not differentially accumulating with C. difficile chronic 
colonization. The chronic inflammation induced by the C. difficile persistence in both 
humans and mice is an open field for further research and may contribute to the clinical 
risk evaluation of C. difficile asymptomatic or symptomatic carriers in the long term. 
 
5.2 Conclusion  
In this project, we demonstrate that chronic colonization of toxigenic C. difficile strains, 
particularly our CRC-associated isolate CIm_2663, but not the non-toxigenic strain, induce 
colon tumorigenesis in ApcMin∆716/+ mice without forming a biofilm structure. Persistent C. 
difficile toxin A and toxin B production and mucosal inflammation correlate with colon 
tumor multiplicity. A chronic inflammatory response, likely provoked by C. difficile toxin A 
and/or toxin B, is marked by accumulating macrophage infiltration and crypt hyperplasia, 
both considered to play a role in pro-carcinogenesis. Collectively, Figure 5.1 displays our 
current model for potential mechanisms by which C. difficile induces colon tumorigenesis. 
 
5.3 Future directions  
Prior investigations (Martin-Verstraete et al. 2016; Darkoh et al. 2015) have shown that 
C. difficile toxin production is largely regulated by the environment such as by nutrients, 
antibiotic treatment, temperature and pH. In this study, we present data showing a clear 
tumorigenic phenotype driven by toxigenic C. difficile strains that persistently produce 
toxin A and toxin B in vivo. Therefore, one of the future directions is to compare the tumor 
multiplicity and longitudinal toxin production in the feces from mice colonized with different 
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C. difficile strains under different environmental conditions such as diverse antibiotic 
regimens. An important next step is to discern the contribution of toxin A and toxin B in 
tumorigenesis by generating isogenic strains including tcdA+ tcdB-, tcdA- tcdB+, and tcdA- 
tcdB- as compared with the parental CRC-associated isolate CIm_2663. As noted, the 
isolation and evaluation of immune cell populations from mouse colonic mucosa by high 
parameter flow cytometry and/or RNA-Seq analyses will enable us to further understand 
the specific immune cell biological activities induced by differing C. difficile strains, the 
contribution of toxin A and/or toxin B to mucosal inflammation in ApcMin∆716/+ mice and, 
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